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 Cardiovascular disease (CVD) exerts economic and humanitarian costs that are 
unparalleled by any other disease. Of the many etiologies of CVD, myocardial infarction 
accounts for over 50% of the associated mortality and anything that can decrease the 
extent of infarction could drastically impact the burden of CVD. The purpose of this work 
was to further our understanding of the role of cardiac mitochondria in 
ischemia/reperfusion injury. Herein I found that physiologic (exercise) and 
pharmacologic (Bendavia) interventions that lessen the oxidative burden during 
ischemia/reperfusion have the potential to limit myocardial infarction. Under conditions 
of oxidative stress, animals who received short term exercise (Ex) were better able to 
maintain the glutathione couple in a reduced state, likely through an increase in 
glutathione reductase (GR) activity. This phenotypic change was associated with 
decreased reactive oxygen species (ROS) accumulation and a lower incidence of fatal 
ventricular arrhythmias. Furthermore, I found that ROS generated within the cytosol, 
and not the mitochondria, during bouts of Ex are important signaling molecules that 
increase GR activity and this increased activity may be responsible for the 
ii  
cardioprotective effects observed with Ex. Finally, I found that treatment with the 
mitochondrially-targeted peptide Bendavia was successful at lowering infarct size in 
isolated guinea pig hearts, due to an ability to decrease ROS accumulation and 
maintain mitochondrial energetics. Taken together, these studies suggest that therapies 
aimed at decreasing mitochondrial ROS and/or maintaining mitochondrial energetics 
during ischemia/reperfusion may have significant clinical impact. 
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Chapter 1: Introduction 
   
Prevalence of cardiovascular disease 
 Cardiovascular disease (CVD) exerts economic and humanitarian costs that are 
unparalleled by any other disease. Ischemic heart disease costs an estimated $165 
billion per year, with physical inactivity accounting for approximately 10% of this cost 
(162), making a sedentary lifestyle a multi-billion dollar problem and highlighting the 
need to promote exercise as medicine within populations at risk. In 2005, approximately 
1 out of every five deaths in the United States was due to coronary heart disease (162). 
Since CVD represents such a burden on the well being of the human population, further 
investigation into how to decrease either the prevalence or mortality associated with 
CVD is of grave importance. 
Coronary heart disease 
accounts for the majority of 
deaths due to CVD (Figure 1), 
and ischemia/reperfusion injury 
resulting from treatment for 
coronary heart disease is the 
focus of this dissertation. 
Ischemia/reperfusion injury: What is it? 
Myocardial ischemia occurs when the blood supply to the myocardium is 
insufficient to match the metabolic demand. Ischemia is an appropriate term as it stems 
from the Greek ischo (to hold back) and haima (blood). The primary event that leads to 
 
Figure 1: Percentage breakdown of deaths due to CVD (United 
States: 2006, preliminary). Taken from (162). 
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obstruction of a coronary artery is generally due to thrombus formation over a 
preexisting atherosclerotic plaque. The formation of the atherosclerotic plaque and 
development of coronary artery disease are beyond the scope of this work and are 
described in detail elsewhere (226). This thrombotic blockage prevents blood flow from 
reaching downstream tissues and predisposes them to cell death. The onset of cellular 
death during ischemia can begin as early as 15 minutes from the onset of symptoms, 
and as duration of ischemia 
increases, the probability of cell 
death also rises (111).  
Importantly, both short- and long-
term mortality are inversely 
proportional to the size of the 
infarction (21, 97, 98, 113, 114). 
Various mechanisms are 
involved in cellular death during 
ischemia and reperfusion and are 
discussed below (see also Figure 
2 and Figure 4).  
 During ischemia the heart tries to compensate by matching its demand with the 
decreased supply by decreasing contraction and switching from aerobic to anaerobic 
metabolism. However, due to the decreased coronary flow, metabolite washout is 
diminished in the ischemic tissue. This combination of increased anaerobic metabolism 
and decreased washout leads to a net increase in proton concentration and CO2 within 
 
Figure 2: Mechanisms by which myocardial ischemia can 
lead to cell death and myocardial infarction. From (200) 
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cardiac tissue, effectively lowering intracellular pH (62). This decrease in pH lowers the 
myofilaments sensitivity to calcium and decreases contractile force (6, 84, 151). 
During ischemia, mitochondrial metabolism is diminished (due to decreased 
oxygen delivery required for oxidative phosphorylation) and ATP levels being to fall, 
When this occurs, ATP-sensitive potassium (KATP) channels on the sarcolemmal 
membrane open, allowing K+ to freely leave the cell. Coupled with decreased metabolite 
washout, K+ accumulates in the extracellular space, decreasing the Nernst potential for 
K+, depolarizing the membrane potential and shortening of the action potential duration. 
Intracellular calcium levels also rise during ischemia, likely due to a combination of 
decreased reuptake into the SR (because of diminished ATP levels) with no change in 
its release from the ryanodine receptor (6, 151). This increased calcium can lead to 
ischemic contracture and an increase in the likelihood that the mitochondria will undergo 
permeability transition. 
Currently the best treatment for myocardial ischemia is prompt reperfusion. 
However, reestablishing coronary flow can lead to further injury, such as myocardial 
stunning, fatal ventricular arrhythmias, and further cell death.  These etiologies may be 
due, in part, to the “bursts” of reactive oxygen species (ROS) that occur in the early 
stages of reperfusion (283, 284). In Chapter 5 (see Figure 22 below) I show that, in 
untreated cells, ROS accumulation is observed prior to cell death during reoxygenation 
and that this reoxygenation injury can be prevented if mitochondrial ROS accumulation 
is prevented. The ability to decrease ROS accumulation during reperfusion is 
associated with decreased injury and is the focus of this dissertation.  
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Role of the mitochondria in health and disease  
Mitochondria are important regulators of cell life and death that respond to a wide 
variety of stress signals, including loss of growth factors, hypoxia, oxidative stress, and 
DNA damage (101). The main role of the mitochondria is to generate enough ATP 
through oxidative phosphorylation and the mitochondria has thus earned the nickname 
“The Powerhouse of the Cell”. In cardiomyocytes, mitochondria account for 
approximately 30% of the intracellular volume, presumably reflecting the high energy 
demand of contraction that the heart undergoes on a beat-to-beat basis. However, 
during oxidative phosphorylation approximately 0.4-4% of molecular oxygen (O2) 
consumed is reduced by a single electron transfer to form superoxide (140). 
During oxidative phosphorylation, mitochondria set up a membrane potential 
(∆Ψm) by pumping protons from the matrix to the inner membrane space. This ∆Ψ m is 
what drives the ATP synthase to synthesize ATP. However, during metabolic stress, 
fluctuations in ∆Ψ m have been observed in whole hearts (38, 237) and isolated 
myocytes (9).  These depolarizations in ∆Ψm drop cellular levels of ATP and can induce 
action potential heterogeneity by opening sarcolemmal ATP-sensitive potassium (KATP) 
channels (3, 199).  As action potential lability is a prime substrate for the formation of 
reentrant arrhythmias (3), interventions that stabilize ∆Ψm diminish electrical 
dysfunction during an oxidative challenge (38).  In Chapter 3, I show that short-term 
exercise training is associated with a phenotype where glutathione is maintained in a 
reduced state due to an increase in glutathione reductase activity. It is expected that 
this would lead to improved maintenance of mitochondrial energetics and is responsible 
for the decrease in arrhythmogenic events. 
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Role of glutathione system  
Glutathione (GSH) represents the largest capacity thiol buffer in the heart (229) 
and exerts a significant effect on mitochondrial function (9, 237). Under normal 
conditions, the balance of reduced (GSH) and oxidized (GSSG) highly favors the 
reduced state (69) and recent data implicates the glutathione redox couple as a 
“pivoting point” between ROS balance and mitochondrial dysfunction (9, 11, 143, 237). 
The importance of maintaining a high GSH:GSSG ratio has been highlighted elsewhere 
(38, 46), but it is interesting to note that the mitochondrial permeability transition pore 
(PTP) opening is sensitized during oxidative stress (172) and significant oxidation of the 
GSH couple (GSH:GSSG of < 50:1) has been shown to trigger PTP opening (9). 
Despite the fact that several studies have shown that superoxide reduction to 
H2O2 through MnSOD is increased with Ex (41, 87, 220, 271), the effect of Ex on H2O2 
scavenging by the glutathione system remains unclear (131, 221, 241). Recently, we 
showed that uncompensated oxidation of reduced GSH can induce catastrophic 
ventricular arrhythmias, even under normoxic conditions (38). In Chapter 3, I describe 
how Ex preserved GSH in a reduced state under similar conditions and protected hearts 
from fatal ventricular arrhythmias. This was associated with decreased ROS 
accumulation and an increase in GR activity. Interestingly, administration of exogenous 
glutathione (GSH) (232) or its precursor, N-acetyl cysteine (72), has resulted in 
decreased injury in animal models. Since there is little de novo synthesis of GSH within 
cardiac tissue (99) the ability of the mitochondria to replenish GSH is of significant 
importance and is the focus of Chapters 3 and 4. 
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To investigate if decreasing mitochondrial ROS during reperfusion presents a 
good pharmacological target, we utilized the novel mitochondrially-targeted peptide 
Bendavia. In Chapter 5, I describe that treatment with Bendavia decreased the ROS 
accumulation in cardiomyocytes, enhanced the ability to maintain mitochondrial 
energetics, and was associated with decreased cell death. 
Exercise as a therapy  
 The ability for exercise to confer protection from I/R injury is described in detail in 
Chapter 2. Despite significant advances in our understanding of the preconditioning 
phenomenon, none of the experimental preconditioning strategies put forth have 
improved therapeutic treatments for patients (80).  One potential reason for this lack of 
translation to clinical practice is the short-lived effectiveness of most preconditioning 
stimuli (60, 255).  Exercise remains one of the few sustainable strategies shown to 
precondition the heart against ischemia/reperfusion injury. Data from our group (43, 44) 
and others (104, 220) have demonstrated that short term exercise is cardioprotective, 
and that this is sustained if exercise continues for months (41).  We believe that by 
studying the mechanisms involved in exercise-induce preconditioning we can uncover 
novel and sustainable preventative treatments for those who cannot or will not adhere to 
an exercise regimen.  
In the United States the proportion of individuals engaging in physical activity 
declines with age and physical inactivity is responsible for approximately 10% of the 
global burden of myocardial infarction after accounting for other CVD risk factors (162). 
Epidemiological evidence supports the notion that patients who exercise regularly are 
more prone to survive a myocardial infarction (183), and have a significantly lower 
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incidence of sudden cardiac death (103).  This protection has also been well 
documented in animal models, as training confers resistance against several different 
indices of ischemia/reperfusion injury, including infarction (for review see (45, 87) and 
Chapter 2), stunning (35, 41, 106, 157), and arrhythmias (105, 118, 194, 220).  While 
the cardioprotective effect of exercise are clear, the cellular mechanisms responsible for 
the protective phenotype have not been elucidated.  
Central Hypothesis  
The goal of this dissertation is to advance our understanding of the role that 
cardiac mitochondria play in exercise preconditioning.   The overriding hypothesis is that 
ischemia/reperfusion injury is mediated by a mitochondrial overload of ROS that 
collapse mitochondrial energetics, and therapies that can reduce this oxidative burden 
will prevent cell death.  In Chapter 3, I establish that maintenance of reduced 
glutathione through the glutathione reductase reaction may be the mechanism by which 
exercise confers protection from ventricular arrhythmias. Chapter 4 sheds valuable 
insight into the role of cytosolic ROS as signaling molecules that modify GR activity and 
confer protection from myocardial infarction. In Chapter 5, I describe the effects of a 
novel pharmacological treatment for I/R injury that decreases mitochondrial ROS 
accumulation.  
 
  
Chapter 2: Exercise-induced cardiac preconditioning: How exercise mends your 
achy-breaky heart 
 From Chad R. Frasier, Russell L. Moore, and David A. Brown.  Exercise-induced 
cardiac preconditioning: How exercise can mend your achy breaky heart.  Journal of 
Applied Physiology, 2011; 111(3): 905-915 (PMID 21393468). (87) 
 
Introduction 
 
The benefits of exercise in promoting health are well documented throughout 
human history.  Various forms of exercise were prescribed by the ancient Chinese, 
Indians, Greeks, and Romans, making exercise arguably the oldest therapeutic 
intervention for the treatment or prevention of disease (160). As our understanding of 
the cardiovascular system evolved, so too did the notion that the overall health of the 
cardiovascular system could be improved with exercise. Beginning as early as the 
1850s exercise was prescribed specifically for the prevention of heart disease in 
Scotland and Scandinavia, and later in the mountain resorts of Germany (160).  In the 
United States, the public health pioneer Dr. James M. Anders was among the first to 
recognize the beneficial effects of exercise medicine.  In a 1904 speech, Anders noted 
that, “It should ever be a feature of our therapeutic creed, to give close attention to 
physiologic means and to recognize their superiority over drugs as curative agencies” 
(7).   
Fast forward a century and one will find an obesity and diabetes epidemic 
sweeping through industrialized nations, with physical inactivity now recognized as a 
major risk factor for cardiovascular disease.  Recent estimates suggest that 
approximately 12% of the cost of cardiovascular disease can be attributed to physical 
inactivity (275), making physical inactivity a multi-billion dollar problem.  A significant 
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amount of time, effort, and resources are being devoted to preventative methods 
seeking to reduce the burden that ischemic heart disease places on both our species 
and our health care system.  In this review article, we seek to summarize the current 
literature regarding the ability of exercise to delay/reduce cardiac ischemia/reperfusion 
injury; in short, we will describe how exercise can make “achy” hearts a little less 
“breaky”.   
Before we begin, it should be noted that exercise is known to reduce arrhythmia 
(105, 194, 220), decrease myocardial stunning (35, 165), and improve coronary 
vascular reactivity (42, 147, 148) in hearts exposed to ischemia/reperfusion. Several 
recent papers have discussed exercise cardioprotection (14, 25, 215, 216, 242), and 
many of these articles have focused on other indices of ischemic injury besides cell 
death.  In this mini-review, we will focus almost exclusively on the ability of exercise to 
confer resistance against infarction.  In the first half of this review, we provide a 
comprehensive overview of the exercise type, duration, and intensity needed to protect 
the heart. In the second half, we discuss underlying cellular mechanisms responsible for 
exercise cardioprotection.  We highlight new insights into how exercise may trigger and 
mediate protection against infarction, and we discuss the time-course of cellular events 
during ischemia and reperfusion that may be altered in the heart after exercise.  Finally, 
throughout this review we point out areas where future research can augment our 
understanding of exercise-induced cardioprotection. 
Can we really ‘precondition’ the heart against infarction? 
 
In the scientific literature, a growing number of strategies have been found to 
protect the heart from ischemia/reperfusion injury.  Among the first of these strategies is 
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the “preconditioning” phenomenon, first noted by Murry et al. (186), where short 
ischemic episodes before a long index ischemia decreased infarction.  A number of 
stimuli have subsequently shown to precondition the heart against injury (reviewed in 
(29)), along with the recent discovery that slowly bringing the heart out of ischemia with 
“post-conditioning” also salvages myocardium (261). Pre/post-conditioning delays the 
onset of ischemia/reperfusion injury, but the extent of protection depends critically on 
the establishment of reperfusion.  In the clinic, prompt reperfusion remains the best 
treatment to salvage tissue, and in experimental settings pre/post-conditioning stimuli 
lose their efficacy to reduce injury with prolonged ischemia (186, 203, 273).  However, 
the re-establishment of coronary flow induces problems of its own (reperfusion injury, 
discussed below), and we will address the etiology of injury during both ischemia and 
reperfusion.   
Naturally, there is enormous interest in trying to ‘mimic’ ischemic pre/post-
conditioning with a compound administered to patients hospitalized for ischemic events.  
Despite scores of potential treatments that are effective in experimental settings, to date 
none of the putative compounds have been incorporated into clinical standard of care.  
The reasons for the lack of translation have been well described elsewhere (80), but the 
correlation between humans who exercise and reduced morbidity/mortality after 
infarction is well documented.  
What is the relationship between exercise and infarct size? 
 
Epidemiological evidence has indicated that there is a strong correlation between 
individuals who exercise regularly and those who survive a myocardial infarction (183, 
205-209).  Elderly humans who are sedentary appear to lose the preconditioning 
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benefits of preinfarction angina, although the protection was seen in counterparts who 
exercised (2, 222).  Given the relationship between infarct size and mortality (112, 178), 
exercise is postulated to promote survival by delaying cell death during metabolic 
challenge, reducing the mass of infarcted tissue.  
Although direct confirmation of exercise-induced infarct sparing is difficult to 
measure in human hearts, several studies have provided indirect evidence of exercise 
cardioprotection in the human heart. Zdrenghea et al. found that exercise-induced ST-
segment depression was significantly attenuated in high risk patients during the 
subsequent exercise bout (276). Lambiase and colleagues exercised patients with 
known coronary artery disease prior to percutaneous coronary intervention, and 
observed that the ST-segment deflection induced by 3-minute intracoronary balloon 
inflation was lessened in the exercised patients (145). Remote preconditioning may also 
protect human heart tissue, as forearm exercises improved ischemic function in isolated 
human atrial trabeculae (224).   
Exercise-induced reductions in infarct size have been observed across animal 
models, corroborating human epidemiological data.  The first observation of exercise 
cardioprotection was noted 8 years before the discovery of ischemic preconditioning 
(IPC) (176),  and has been observed in both male (4, 44, 52, 55, 91, 117, 270, 271) and 
female (39, 42, 44, 55, 106) animals.  Infarct salvage can be seen using both in vivo (4, 
91, 106, 117, 271) and ex vivo (perfused heart) (39, 42, 44, 52, 55, 73, 270) 
preparations of ischemia/reperfusion, indicating that both systemic and intrinsic cardiac 
adaptations are likely responsible for the protective phenotype.  Although most studies 
have used younger animals, the exercise-induced cardioprotection appears to be 
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upheld with aging (150, 218, 244).  This distinction is important, as the vast majority of 
deaths from MI occur in humans over the age of 65.  
On average, the magnitude of protection evoked by exercise preconditioning is a 
30-40% reduction in injury (reviewed in more detail in (45)).  This magnitude in infarct 
size reduction is consistent with many pharmacological treatments aimed to decrease 
injury, but does not appear to be as large in magnitude as classical ischemic 
preconditioning (273).  
Is exercise really the same as ‘preconditioning’? 
 
There are a number of similarities between exercise-induced cardioprotection 
and other preconditioning stimuli. The time-course for protection is very similar across 
models, with a narrow first window of robust protection followed by a ‘second window’ of 
more modest protection (77, 271, 273).  In both IPC and acute exercise preconditioning, 
infarct size is significantly lower within one hour of the stimulus, but this protection 
wanes for approximately 24 hours.  A second window of protection is observed following 
both IPC and exercise preconditioning, and in both cases the second window reflects a 
much wider time frame to observe a preconditioning effect (approximately 24-36 hours 
after the preconditioning stimulus).   
The only studies to examine the time-course for exercise preconditioning used a 
single bout of exercise (77, 271).  Repetitive exercise training over weeks/months 
evokes a number of morphological/phenotypic changes in the myocardium, including 
resting bradycardia, hypertrophy of the left ventricle, cellular growth/adaptations in 
cardiac myocytes, and altered coronary vascular function (39, 42, 147, 168).  These 
changes make it a little more difficult to compare a chronic stimulus with acute stimuli 
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such as classical ischemic preconditioning, and future studies looking to compare the 
time-course for protection following chronic training hope to provide insight into whether 
the protection is still characterized by two distinct windows of preconditioning.   
Although exercise may share some of the mechanistic pathways with IPC (e.g. a 
role for reactive oxygen species; covered in detail below), there are clear distinctions.  
For example, phosphorylation of Akt or GSK-3β has been observed in a number of 
preconditioning models (reviewed in (185)), but neither Akt nor GSK-3β phosphorylation 
appear to be necessary for exercise cardioprotection (39, 61).  Furthermore, increased 
cyclooxygenase-2 (COX2) is seen in several preconditioning models (31), but up-
regulated COX2 was not found to be involved in exercise preconditioning (219).  
Several other characteristics of exercise preconditioning distinguish this 
preconditioning stimulus from the others.  First, any preventative treatment must be 
shown to be sustainable for long periods of time.  Many experimental stimuli appear to 
“precondition” the heart when given one time, but unless our powers to forecast 
impending coronary events improve drastically, the clinical relevance of one-time 
administration of preventative measures must be questioned.  As a preventative 
measure, exposure to exercise protects the heart against infarction after either 1 day, or 
many months of the exercise stimulus.  Second, any potential therapy must be readily 
available to patients, and there is no treatment that is more readily available to patients 
(or more economically affordable) than exercise.  Finally, as addressed above the 
epidemiological evidence is clear that exercise is also protective to human hearts.  
Given these distinctions from classical models of preconditioning, exercise is arguably 
the most clinically relevant preconditioning stimulus that has been studied to date. With 
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such enormous potential, we will now address how much of this stimulus is necessary 
to precondition the myocardium.   
How much exercise is needed to protect the heart? 
 
An interesting (and on-going) challenge is to determine exactly how much 
exercise is needed to evoke protection against I/R injury.  By far, the most common 
exercise model in the literature is forced treadmill running in the rat.  In most studies, 
30-60 minutes of running at treadmill speeds of 27-33 meters per min is used as the 
exercise stimulus (often bookended by 10-15 min of lower intensity running at ~15 
meters per min).  Such protocols consistently confer protection against infarction (see 
below), and reflect an exercise intensity of approximately 75% of VO2max (19).  To the 
best of our knowledge, the influence of lower intensity treadmill running (<60% VO2max) 
on infarct-salvage is not known. Studies examining post-ischemic mechanical recovery 
after lower intensity treadmill running protocols have found equivocal results, with some 
finding improved recovery with exercise (156), and others finding no effect (243).  A 
direct relationship between exercise intensity/duration with infarct salvage must be 
addressed in future studies.  
Unlike skeletal muscle, training adaptations to the heart following treadmill 
protocols are not normally characterized by increased Krebs Cycle intermediates 
(citrate synthase, for example, is not normally increased in trained hearts (146, 195, 
213)), but there are training adaptations such as elevated anti-oxidants (covered in 
detail below) and left ventricular hypertrophy.  The resting bradycardia induced by 
higher intensity treadmill running can even be observed in the isolated heart (39), 
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indicating that intrinsic adaptations to pacemaker currents may also accompany altered 
autonomic nervous system tone.  
Our best insight into how much exercise is needed is provided by studies that 
have used different models, intensities, and durations of exercise and looked at 
increased expression of cardioprotective proteins (such as cellular anti-oxidants and/or 
heat shock proteins).  An exercise intensity of > 24 meters/min (with a treadmill incline > 
2%) appears to be necessary for the upregulation of myocardial heat shock proteins 
(179, 195), although several studies have dissociated the link between exercise-induced 
protection and elevated heat shock proteins (104, 243, 252).  Increased manganese 
superoxide dismutase (MnSOD) is observed in young animals following exercise at 
intensities > 27 meters/min with treadmill incline set at either 0% (92, 117, 220, 271) or 
10% (42, 52).  Increased cardiac MnSOD can be induced at lower treadmill speeds (20-
25 meters/min) if a treadmill incline of > 10% is applied (119, 221), but is not observed 
at treadmill speeds lower than 20 meters/min (54, 156).  
Future research that determines how long exercise cardioprotection persists after 
cessation of an exercise regimen will also improve our understanding of exercise 
preconditioning.  Although no study has directly determined how long exercise-induced 
infarct salvage lasts after stopping exercise, an interesting study from Powers’ group 
investigated the effects of exercise cessation on functional recovery.  In their study, 
Lennon et al. (155) exercised animals for a total of 8 days, with the final 3 days 
consisting of high intensity exercise (30 meters/min for 1 hour).   The beneficial effects 
of exercise (as evidenced by post-ischemic recovery of cardiac work) persisted for 9 
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days after cessation of the exercise, but by 18 days post-exercise there was no longer 
an exercise effect.   
While the cardioprotective benefits of treadmill running protocols are clear, the 
limitations of this model must be clearly recognized.  Animals that do not run on the 
treadmill are often prodded, blasted with air, or shocked via an electrical grid.  The 
caveat that animals may display a stress response following this ‘motivation’ must be 
acknowledged in forced treadmill studies, especially those where exercise only lasts a 
few days.  Only a few investigators have attempted to address this issue, and in both 
cases there was evidence (especially in male animals) of systemic stress (reflected by 
adrenal hypertrophy, splenic atrophy, and increased circulating corticosterone) (43, 
182).  Admittedly, these data are subject to different interpretations (what is ‘stress’ 
versus ‘exercise adaptations’?), and we hope that the dialogue regarding the best 
experimental exercise approach will continue among scientists in this field.   
More work must be done to determine if voluntary wheel running protocols can 
protect the heart against infarction.  Wheel running has the advantage that animals run 
ad libitum, with rats often covering several kilometers per day (153).  The disadvantages 
of wheel running include a much lower intensity of exercise, and variability among the 
amount of exercise that each animal receives. Voluntary wheel running has been shown 
to improve survival after ischemia (67), but future studies are needed to determine if 
voluntary running can protect the heart to the same extent as higher intensity treadmill 
running.  
A few studies have looked at the infarct sparing effects of swimming training.  In 
these studies, animals were exposed to several hours of swimming per day for 7-8 
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weeks, and infarctions were significantly reduced in swim-trained animals compared to 
sedentary counterparts (91, 279).  The limitations of swimming protocols must also be 
acknowledged, as the exercise is often characterized by diving reflexes, animal stress 
from borderline drowning, and intermittent hypoxia (22, 86).  
What is it about exercise that triggers a protective phenotype? 
 
We are only beginning to understand what exercise does to “trigger” a 
preconditioning response.  Exercise-induced activation of adenosine or opioid 
receptors, transient ROS production, AMP kinase, and/or surges in inflammatory 
cytokines are candidate triggers for the protection (a hypothetical schematic is 
presented in Figure 3).  
Several studies 
suggest that receptor-
dependent signaling 
cascades are involved in 
triggering exercise 
cardioprotection. 
Adenosine receptor 
blockade abolished the 
cardioprotection evoked 
by intermittent bouts of 
tachycardia in paced dog 
hearts (78), suggesting that adenosine release at high heart rates initiates a cascade of 
events that confer resistance to infarction. The mechanism of action for adenosine 
 
Figure 3: Putative sequence of events leading to exercise-induced 
cardioprotection. Postulated ‘triggers’ of exercise-induced cardioprotection are 
denoted in green, with end-effectors labeled in red font.  Images of nucleus and 
myofilaments obtained from (24, 266) respectively. 
 18  
receptor activation is surely multi-factorial.  Husain and Somani (121) recently found 
that the increase in myocardial anti-oxidant enzymes after acute exercise was abolished 
when exercise was performed in the presence of an adenosine receptor blocker.  The 
authors did not investigate ischemia/reperfusion injury, and more work is needed to 
determine if adenosine receptors initiate cardioprotective signaling following repetitive 
bouts of exercise.  This is especially important in light of observations where chronic 
administration of adenosine loses efficacy to precondition the myocardium (255).   
Opioids may also play a role in triggering exercise cardioprotection.  A recent 
study found that blocking opioid receptors during the exercise treatment abolished the 
infarct salvage (73).   Endogenous opioids can be released from a number of tissues 
(including heart) (70, 75), and administration of both opioid peptides and opioid receptor 
agonist preconditions tissue against injury (74, 93).  Exercise may increase endogenous 
opioids in the coronary circulation via endocrine/autocrine pathways, although the exact 
role of endogenous opioids in exercise preconditioning warrants further investigation.  
An attractive hypothesis is that the activation of adenosine and/or opioid 
receptors during exercise leads to protection via protein kinase C (PKC)-dependent 
mechanisms.  Adenosine and opioid receptor-signaling both converge on PKC (180, 
260, 272), and the activation/translocation of PKC isoforms may induce a number of 
adaptive changes within the myocardium.  The expression of several PKC isoforms is 
altered in the heart after repetitive exercise (49), and inhibiting PKC before exercise 
abolishes the infarct salvage (177, 270).  Among the different PKC isoforms in the heart, 
several studies suggest a protective role for PKCε in particular (49, 177).  It is not yet 
clear which cellular proteins “down-stream” of PKC may be activated to mediate 
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exercise preconditioning.  PKC-dependent activation of heat shock protein 70 does not 
appear to be an absolute requirement for exercise cardioprotection (177), although 
PKC-dependent activation/trafficking of sarcolemmal ATP-sensitive potassium channel 
may be involved.  Future research that elucidates down-stream PKC targets will 
improve our understanding of its role in exercise cardioprotection.   
 Another putative trigger of exercise preconditioning is the transient release of 
reactive oxygen species (ROS) during exercise.  Several studies have noted that the 
infarct-salvaging affects of exercise, as well as exercise-induced improvements in 
cardiac function are abolished when anti-oxidants are given during the exercise (4, 191, 
271).  Exercise has been shown to increase the activity of myocardial NADPH oxidase, 
and inhibiting NADPH oxidase, a source of reactive oxygen species, abolished the 
protective effects of acute exercise (227).  The notion that a small amount of reactive 
oxygen species may lead to cardiac adaptations that confer resistance to infarction has 
been put forth in other preconditioning models (138), although the mechanisms that 
ultimately lead to decreased I/R damage are yet to be determined.  A small ROS burst 
may increase anti-oxidant buffering capacity by promoting gene expression and protein 
synthesis, similar to the hormesis observed in skeletal muscle (126).  ROS-dependent 
(redox) modulation of the ryanodine receptor after exercise was recently found to 
decrease SR calcium leak (227), although it is not clear if this mechanism is involved in 
delayed exercise cardioprotection (i.e. 24 hours after exercise versus acute effects 
investigated by Sanchez et al. (227)).  
 Adenosine monophosphate-activated protein kinase (AMPK) is another 
candidate ‘trigger’ for exercise preconditioning. AMPK is believed to be quiescent in the 
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heart when energy supply-demand is in balance, but is activated during changing 
metabolic conditions (such as exercise or ischemia; reviewed in (12, 137)). 
Pharmacological activation of AMPK has been shown to reduce infarct size to a similar 
degree as exercise preconditioning (142).  Cardiac AMPK is activated following 
treadmill running, with the AMPKα-2 isoform appearing to be the most responsive (61, 
142, 187). Relating to the cardioprotective mechanism of action, AMPK activation is 
postulated to stimulate glucose/fat metabolism in the heart during metabolic stress (12, 
137), and may promote translocation of cardiac ATP-sensitive potassium channel 
subunits ((246); described in more detail below).  The ischemic heart switches to 
anaerobic glycolysis very quickly, and both glycogen storage and sarcolemmal glucose 
transport are stimulated by AMPK.  During reperfusion, AMPK is believed to augment 
fatty acid uptake and oxidation, further augmenting substrate flux through re-energized 
mitochondria. AMPK activation after exercise may protect the heart through better 
preservation of cardiac energetics, and there is both direct and indirect evidence that 
cellular ATP content is better maintained after ischemia/reperfusion in exercised hearts 
((36, 124); addressed in more detail below).  Inhibiting AMPK activation has not yet 
been shown to abolish exercise preconditioning.  Using an AMPKα-2 dominant negative 
mouse model, Musi et al. found that neither the ability of animals to exercise nor the 
maintenance of cardiac energy stores was altered with AMPKα-2 deficiency (187).   
Future experiments that directly examine exercise cardioprotection in AMPK knockout 
models, as well as development of more specific pharmacological tools that block 
AMPK activation will improve our understanding of AMPK in exercise cardioprotection.  
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The role of cytokines on cardiac ischemia/reperfusion injury in the literature is 
conflicting (65, 169). Regarding the involvement of cytokines in triggering exercise 
induced cardioprotection, Yamashita et al. found that antibodies directed at both TNFα 
and IL-1β abolished exercise-protection when given prior to a single bout of exercise, 
and one-time administration of TNFα has been shown to reduce injury (169, 271).  
Clearly more investigation is needed to clarify the role that cytokines play in exercise-
induced cardioprotection, and whether cytokines such as TNFα are involved in long-
term exercise adaptations (such as cardioprotection or hypertrophy). 
Among the candidate triggers and mediators involved in exercise-induced infarct 
sparing, augmented collateral coronary circulation, elevated nitric oxide synthase, heat 
shock proteins, and ER stress proteins do not appear to be obligatory for protection.  
For the interested reader, several excellent review articles have articulated these 
studies in more detail (216, 242).   
Is exercise-induced cardioprotection due to improved ability to scavenge ROS? 
Superoxide Dismutase.     
 
Exercise appears to improve at least some aspects of cellular ROS scavenging 
systems.  Superoxide production by complexes I and III of the electron transport chain, 
NADPH oxidase, xanthine oxidase, and NOS is believed to contribute to 
ischemia/reperfusion injury in the heart (28).   The “front-line” of cellular superoxide 
detoxification involves enzyme-catalyzed dismutation by superoxide dismutase (SOD).  
Cellular compartmentalization of SOD has led to several distinct isoforms including 
extracellular SOD, copper-zinc (Cu/Zn)SOD in the cytosolic compartment, and 
manganese (Mn)SOD in the mitochondrial matrix.  Among these isoforms, increased 
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MnSOD in particular has been found in many studies to correlate with protection against 
infarction.   
In most exercise preconditioning studies, upregulated MnSOD has been 
observed following exercise.  The duration (number of consecutive days) of exercise 
appears to be a key determinant to altering cardiac MnSOD levels.  As noted in Table 1, 
most (but not all) investigations have observed increased MnSOD activity following 
short-term (one to five days) exercise, but MnSOD mRNA (73) or protein (44) is not 
increased after acute exercise. In studies examining MnSOD with longer duration 
exercise protocols, there is a clear upregulation in both the activity (52, 119, 120, 131, 
149, 213) and protein expression (42).  This ability to augment MnSOD with exercise 
appears to be maintained in the aged heart (100, 131, 149). Supporting evidence for 
augmented MnSOD content and cardioprotection comes from mouse models where 
genetic over-expression of MnSOD protected against infarction (59), and genetic 
knockdown was associated with increased necrosis and impaired cardiac function 
(164).  
Even within the same study, increased MnSOD activity can be observed without 
increased protein expression (271). Post-translational modification of MnSOD is known 
to affect enzyme activity (267), and future experiments will help to determine if post-
translational modifications of MnSOD (such as de-phosphorylation) are involved in the 
exercise-induced increase in MnSOD activity.  As with exercise cardioprotection, 
upregulation in either the activity or protein content of MnSOD appear to be critically 
dependent on the intensity of exercise, as low-intensity treadmill running (54, 156, 213) 
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and voluntary free wheel running (130) do not appear to increase myocardial MnSOD 
levels.   
Pharmacological SOD mimetics show promise as a cardioprotective treatment 
across models of I/R (27, 53, 129, 136, 141).  In recent human clinical trials, exogenous 
ROS scavengers decreased short-term injury (256), although there didn’t appear to be a 
long-term benefit. Further development of SOD mimetics, especially mitochondria-
specific ROS scavengers (248), has potential in mitigating cardiac I/R injury.   
Table 1: Changes in myocardial MnSOD after exercise 
Study (ref.) Animal  
(sex) 
Exercise  
Duration/type 
Cardiac MnSOD change following 
exercise (method employed) 
SHORT-DURATION 
EXERCISE STUDIES 
   
Yamashita et al. (271) rat (M) 1 d treadmill Early Phase: increased (activity), NC 
(protein) 
Late Phase: increased (activity and protein) 
Dickson et al. (73) rat (M) 1 d treadmill NC (mRNA) 
Hoshida et al. (117) rat (M) 2 d treadmill Increased (activity; early and late phase) 
Quindry et al. (220) rat (M) 3 d treadmill Increased (activity) 
Lennon et al. (156) rat (M) 3 d treadmill NC: low intensity running (activity) 
Increased: high intensity running (activity) 
Demirel et al. (68) rat (F) 3-5 d treadmill Increased (activity) 
French et al. (92) rat (M) 5 d treadmill Increased (activity) 
Brown et al. (44) rat (M and F) 1 or 5 d treadmill NC (protein content) 
LONG-DURATION 
EXERCISE STUDIES 
   
Husain (119) rat (M) 8 wk treadmill Increased (activity and protein) 
Ramires and Ji (221) rat (F) 10 wk treadmill Increased (total SOD activity) 
Chaves et al. (52) rat (M) 10 wk treadmill Increased (total SOD activity) 
Kakarla et al.  (131) rat (F) 12 wk treadmill Increased (total SOD activity) 
Chicco et al. (54) rat (M) 12 wk treadmill 
(low intensity) 
NC (protein) 
Lawler et al. (149) rat (?) 12 wk treadmill Increased (activity and protein) 
Starnes et al. (241) rat (M) 16 wk treadmill NC (total mitochondrial SOD activity) 
Brown et al. (42) rat (F) 20 wk treadmill Increased (protein content) 
Gunduz et al. (100) rat (M) 1 yr swimming Increased (total SOD activity) 
Vaanholt et al. (257) mouse (M)  life-long wheel NC (total SOD activity) 
Judge et al. (130) rat (M) life-long wheel Decreased (activity) 
 
 
Abbreviations: NC, no change; SOD, superoxide dismutase; ?, sex not disclosed. 
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Augmented H2O2 Scavenging 
 
Heightened SOD capacity appears to be involved in exercise cardioprotection, 
but there is little evidence of increased enzymes responsible for converting the SOD 
reaction product, H2O2, to water.  In the myocardium, enzymatic detoxification of H2O2 
depends on catalase, glutathione peroxidase, and thioredoxin. Only a few studies have 
noted increased catalase in the heart after exercise training (119), with most studies 
finding no difference in myocardial catalase activity after exercise (68, 92, 106, 130, 
220, 221, 251).  Most studies also find no change in glutathione peroxidase in the heart 
(68, 92, 106, 130, 220, 241, 251), consistent with observations where genetic over-
expression of glutathione peroxidase did not confer protection against infarction (129).   
Finally, although there has not been as much investigation into cardiac thioredoxin with 
exercise, it also appears to be uninfluenced by exercise (68).  Taken together, 
heightened enzymatic scavenging of H2O2 does not seem to be a requisite for exercise-
induced cardioprotection.   
Glutathione and Glutathione Reductase 
 
 Exercise has been shown to increase total cardiac glutathione content (221), 
although this too appears to be intensity-dependent as increased glutathione was not 
observed with life-long wheel running (130).  It is not clear glutathione reductase is 
involved in exercise cardioprotection, with some studies finding that glutathione 
reductase increases with exercise (131, 221) and others finding no change (52, 68, 
130).  Further work, especially those comparing glutathione content during/after 
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oxidative stress, may provide more insight into glutathione and exercise 
cardioprotection.   
Are ATP-sensitive potassium channels involved in exercise cardioprotection?  
 
 A candidate protein complex that appears to be involved in exercise 
cardioprotection is the family of cardiac ATP-sensitive potassium (KATP) channels.  In 
the heart, there is one family of KATP channels in the sarcolemmal membrane 
(sarcKATP), and another in the mitochondrial inner membrane (mitoKATP) (122, 196). 
SarcKATP channels couple the metabolic status of the cell to the electrical excitability, 
and may be part of a negative feedback mechanism utilized by cells to shorten the 
action potential and reduce excitability when energy supplies fall (see (198) for a review 
of KATP channels in cardiac preconditioning,).  KATP-dependent truncation of the action 
potential is believed to reduce cellular calcium levels by reducing L-type calcium 
transients. Functional cardiac sarcKATP channels are believed to exist as hetero-
octomers, with 4 pore-forming subunits and 4 accessory subunits inserted into the 
sarcolemma.  Heart-specific isoforms were originally thought to consist of Kir6.2 pore-
forming subunits, and SUR2a accessory subunits, although recent findings indicate that 
the molecular identity of cardiac sarcKATP may be more complicated and include 
multiple isoforms of both pore-forming (Kir) and accessory (SUR) subunits (278).   
Several studies support a role for sarcKATP channels in exercise preconditioning.  
Genetic knockout of sarcKATP pore-forming subunits confers exercise intolerance (282), 
and upregulation of KATP channel subunits has been observed following both short-term 
and chronic exercise (39, 44).  A confirmatory role for sarcKATP channels in exercise-
induced cardioprotection is provided in both short-term (55) and long-term (39) exercise 
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studies where pharmacological block of sarcKATP channels abolished the 
cardioprotection.  In isolated cardiac myocytes exposed to I/R, Libonati et al. showed  
 
A. 
 
B. 
 
Figure 4: Pathophysiological changes in rodent cardiac tissue during ischemia (A) and reperfusion (B). Postulated 
mechanisms involved in exercise-preconditioning noted in red font.  Heart image modified from (170).  
Abbreviations: ∆Ψ p, sarcolemmal membrane potential, ∆Ψ m, mitochondrial membrane potential; sarcKATP, 
sarcolemmal ATP-sensitive potassium channels. 
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that myocytes from trained animals had shorter action potentials than sedentary 
counterparts, consistent with the notion that exercise may protect the heart by 
augmenting the ability to repolarize (159). The issue of sarcKATP channel subunit 
trafficking should be addressed in future exercise studies, as both PKC (82) and AMPK 
(246) have been shown to translocate sarcKATP subunits to the sarcolemma and induce 
cardioprotection in other preconditioning models.    
Sarcolemmal KATP channel opening during ischemia appears to be the crucial 
time-point to protect tissue against infarction, as blocking the channels during 
reperfusion alone doesn’t influence infarct size (127).  During the ischemic period, there 
is probably a relatively short window for KATP channels to protect the heart.  In rodent 
hearts exposed to ischemia, electrical activity in ventricular tissue continues for 
approximately 15 minutes, although mechanical function stops within in the first 2 
minutes.  Conduction velocity slows during ischemia due to the closure of gap junctions 
(“cellular uncoupling”) (50), and after approximately 15-20 minutes of ischemia cells 
become inexcitable due to run-down of sarcolemmal ion gradients and gradual 
sarcolemmal depolarization secondary to ATP depletion (see Figure 4).  This loss of 
electrical excitability is best observed in global ischemia models (37), and is along the 
same time-line as the onset of ischemic contracture.  Given the small window for 
sarcKATP-dependent protection, sarcKATP opening likely reduces infarction by delaying 
the onset of injury, although this delay may be inconsequential after prolonged ischemia 
(203).  While speculative, this would explain why KATP channel block during longer 
ischemic bouts did not influence infarct size in sedentary male hearts (55, 127), as 
sedentary male rats are the most susceptible to injury and the window of protection from 
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KATP channel opening may have passed during prolonged injury.  Despite a higher 
propensity for injury in male animals (127), exercised male hearts still show increased 
sarcKATP channel expression (44), and blocking sarcKATP channels during ischemia 
abolishes the exercise preconditioning in both sexes (39, 55). 
Although the opening of KATP channels reduces cellular injury, the consequence 
of increasing KATP currents may introduce electrical heterogeneity in the heart and 
promote arrhythmia, especially during reperfusion (reviewed in (46)).  Regarding the 
ischemic versus reperfusion opening of KATP channels, it seems plausible that blocking 
sarcKATP channels during ischemia delays calcium overload and decreases infarction 
(127), while blocking sarcKATP channels during reperfusion has negligible effect on 
infarction but maintains cardiac function secondary to preservation of electrical stability 
(as observed in (125)).   
Unlike a number of other preconditioning models (reviewed in (197)), blocking 
the mitochondrial KATP channel during I/R did not influence exercise-induced protection 
from infarction (39).  Interestingly, administration of a mitoKATP blocker during exercise 
(versus during I/R) does abolish the protection (77), indicating that mitoKATP activation 
might be involved in triggering the protective phenotype, but is not involved during the 
ischemic insult.  It is important to note that the compound used as a ‘specific’ blocker of 
mitoKATP (5-hydroxydecanoate) is notoriously non-specific (39, 108-110). Future 
experiments using a better pharmacological approach, as well as improved insight into 
the molecular identity of mitoKATP, will advance our understanding regarding the 
involvement of mitoKATP in exercise preconditioning.   
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Does prior exercise protect against cellular calcium overload? 
 
Cellular calcium overload is central to the etiology of ischemia/reperfusion 
damage (reviewed in (201)). There is surprisingly little information regarding the effects 
of exercise on myocardial calcium handling during pathological circumstances.  Jew and 
Moore (125) found no difference in cellular calcium content between sedentary and 
trained hearts exposed to I/R, although the method employed indicated only the total 
calcium content (and does not indicate if compartmentalization of calcium, i.e. to the 
mitochondria, occurred).  Consistent with these findings, Libonati et al. (159) found no 
difference in cellular calcium transients in myocytes from sedentary and trained animals, 
although these measurements were done in myocytes isolated after experimental I/R.  
Bowles and Starnes (36) used radiolabeled calcium isotopes and found that the 
exercise trained heart appeared to be less-susceptible to calcium overload after 30 
minutes of reperfusion.  One of the best physiological correlates to calcium overload is 
increased left ventricular diastolic pressure, and exercise does appear to protect the 
heart from diastolic dysfunction during I/R (42). Clearly much more investigation is 
warranted regarding the time-specific changes in cardiac calcium handling in hearts 
exposed to I/R to determine if prior exercise effectively delays the time-course for 
calcium overload after the onset of ischemia.  
What is the role of cardiac mitochondria in exercise preconditioning? 
 
Exercise evokes adaptations in cardiac mitochondria that likely contribute to 
exercise-induced cardioprotection. While increases in Krebs Cycle intermediates are not 
observed after exercise in the healthy heart, a number of exercise-induced changes in 
mitochondrial proteins associated with apoptosis and ROS scavenging have been 
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observed (134).  Interestingly, the subsarcolemmal population of mitochondria appeared 
to have more changes than the interfibrillar population of mitochondria (133). While 
there is much work to be done to understand how the altered mitochondrial proteome 
leads to infarct sparing, there are clearly phenotypic changes to mitochondria following 
exercise training. Isolated mitochondria from exercised animals are more resistant to 
apoptotic stimuli (134, 279).  Whether or not delayed permeability transition pore 
opening (PTP) is a characteristic of mitochondria from exercised animals is equivocal, 
with some investigators finding no change in mitochondrial calcium tolerance (241) and 
others finding that mitochondria from exercised animals have a greater calcium 
retention capacity (134, 171).  A likely explanation underlying differences between 
studies is the experimental methods employed.  Starnes et al. (241) found no 
differences in calcium tolerance after administering one calcium pulse (200nmol/mg 
mitochondrial protein) to de-energized mitochondria.  Both Marcil et al. (171) and 
Kavazis et al. (134) found that PTP opening was delayed after training, but only when 
mitochondria were respiring on the complex II substrate succinate.  Given the 
heightened ROS production with succinate-supported respiration, an improvement in 
endogenous ROS scavenging capacity is likely the culprit behind delayed PTP opening 
in these studies.   
Taken together, mitochondria from exercised animals appear to be more 
resistant to injury, and it is likely that this healthier population of mitochondria is better 
able to preserve cellular energetics during oxidative stress (Figure 4).  Preservation of 
energetics after exercise is reflected by a slower decline in myocardial ATP levels 
during ischemia/reperfusion (35), maintenance of cardiac oxygen consumption after 
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ischemia (36), prolonged time-course for sarcKATP channel opening during cellular 
anoxia (124), and resistance to apoptotic stimuli (134).  
Conclusion 
 
 Exercise training is one of the few preconditioning stimuli that evokes sustainable 
protection against cardiac ischemia/reperfusion injury.  Improved oxidant buffering 
capacity, decreased cellular/mitochondrial calcium overload, and preservation of 
bioenergetics all appear to be involved in the underlying mechanisms.  There is 
arguably no stimulus, whether pharmacological or physiological, that can promote such 
potent and long-lasting protection to hearts.  Continued research into the mechanisms 
underlying exercise-induced cardioprotection, as well as novel pharmacological agents 
that are effective in exploiting these mechanisms, will improve our ability to treat those 
achy, breaky hearts.  
  
  
Chapter 3: Short-term exercise decreases arrhythmias following thiol oxidation 
and ischemia in isolated rat hearts 
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Kurowicki, Steven LoPresto, Ethan Anderson, and David A. Brown. Short-term exercise 
preserves myocardial glutathione and decreases arrhythmias following thiol oxidation 
and ischemia in isolated rat hearts. Journal of Applied Physiology, 2011; 111(6): 1751-
1759 (PMID 21940849). (89) 
 
 
Introduction 
Sudden cardiac death due to sustained ventricular arrhythmia is a significant cause 
of mortality following a myocardial infarction, especially in patients with underlying 
cardiovascular disease (162).  Epidemiological evidence indicates that humans who 
exercise regularly are more prone to survive a myocardial infarction (183), likely due to 
a significantly lower incidence of sudden cardiac death among exercised individuals 
(103).  The cardioprotective effect of exercise training is also well documented in animal 
models, as exercise confers resistance against several different indices of 
ischemia/reperfusion injury including infarction (for review see (45, 88)), myocardial 
stunning (35, 41, 106, 157), and arrhythmia (reviewed in (25)).  With regards to the anti-
arrhythmic effects of exercise, several studies have noted that exercise evokes an anti-
arrhythmic phenotype characterized by lower incidence of ventricular arrhythmia (25, 
105, 118, 220) and increased ventricular fibrillation threshold (194).  Despite the clear 
association between exercise and resistance to arrhythmia, the cellular mechanisms 
have not been fully elucidated.  
Although prompt reperfusion remains the best treatment of an ischemic event, 
abrupt flow restoration is associated with a burst of reactive oxygen species (ROS) that 
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is believed to be partly responsible for reperfusion injury (245, 283). This ROS burst 
may lead to fatal arrhythmias (reviewed in (46)), and strategies that improve 
mitochondrial ROS scavenging have clear potential in mitigating electrical dysfunction. 
Exercise has been shown to decrease ROS-mediated myocardial damage (251), but an 
explanation of how improved tolerance to an oxidative insult protects exercised hearts 
against arrhythmia has not been provided.   
  Cardiac glutathione represents the largest capacity thiol buffer in the heart (229) 
and exerts a significant effect on mitochondrial function (3, 47). Recent data implicates 
the glutathione redox couple as a “pivoting point” between ROS balance and 
mitochondrial dysfunction (9, 11, 143, 237). During conditions when ROS generation 
exceeds scavenging capacity (such as early reperfusion), ROS-mediated opening of 
energy-dissipating ion channels in the inner mitochondrial membrane  leads to instability 
in mitochondrial membrane potential (∆Ψ m) (10).  Oscillations in ∆Ψ m activate 
sarcolemmal ATP-sensitive potassium (KATP) channels and can induce lability in the 
cardiac action potential (3, 10), a prime substrate for re-entrant arrhythmia (46).   
Previous investigations found that collapses in ∆Ψ m occur when the reduced/oxidized 
glutathione ratio (GSH/GSSG) reaches a ‘critical’ level, and our previous work indicated 
that chemically oxidizing the cellular thiol pool induced ventricular arrhythmias under 
otherwise normoxic conditions (38).  Pharmacological treatments that sustain 
GSH/GSSG have been shown to stabilize ∆Ψ m (9, 38, 94), and prevent arrhythmias 
(38), but whether a physiological stimulus such as exercise can reduce arrhythmia by 
maintaining GSH/GSSG is not known.    
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Given the important influence that glutathione can exert on cardiac electrical 
activity, we conducted this study to determine if the anti-arrhythmic effects of short-term 
exercise were due to an improved tolerance to oxidative stress by the cardiac 
glutathione system. We hypothesized that 10 days of exercise would reduce 
arrhythmias evoked by either chemical oxidation of glutathione or ischemia/reperfusion.  
We also postulated that isolated myocytes from exercised animals would show 
diminished ROS emission and improved viability during cellular oxidative challenge, and 
that this protective phenotype would be associated with maintenance of ROS-buffering 
capacity by the glutathione system.   
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Methods  
Experimental Animals 
Female Sprague-Dawley rats (150-250g) were housed on a 12:12 hour light-dark 
cycle with food and water provided ad libitum. All experiments were conducted in 
accordance with guidelines established by the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85–23, revised 1996), and with prior approval from East Carolina University’s 
Animal Care and Use Committee.  
Exercise Protocol 
 Rats were randomly assigned into one of two experimental groups: sedentary 
control (Sed) or short-term exercise (Ex). Exercise was performed on a motorized 
treadmill similar to a well-established protocol (40). We chose an exercise protocol 
consisting of 10 days of running, because our previous work indicated that this protocol 
evokes both a cardioprotective phenotype and skeletal muscle adaptation to the 
exercise while minimizing the stress response in female rats (43).  Following 3 days of 
acclimation to the treadmill (15m/min for 5, 10, and 15 minutes for days 1, 2, and 3, 
respectively), Ex animals 
received 10 consecutive 
days of treadmill running (6% 
grade) using the protocol in 
Figure 5. 
Animals that did not run were placed back on the moving treadmill using 
prodding or a mild shock via the shock grid at the end of each running lane. Sed 
 
Figure 5: Exercise protocol used in this study. 
   
15 min 30 min 15 min 
15 m/min 30 m/min 15 m/min 
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animals were handled and placed on the stationary treadmill for 5 minutes each day for 
10 days.  
Experimental Groups 
 A total of 71 rats were used in the study.  Following 10-days of exercise (or 
handling control), experimental animals were used in one of the following six study 
arms: 1. Whole heart diamide perfusion until the heart went into a sustained (greater 
than 10 seconds) ventricular arrhythmia (n = 8 Sed and 8 Ex); 2. Whole heart diamide 
perfusion for 39 minutes (n = 8 for Ex only); 3. Whole heart diamide perfusion for 30 
minutes followed by a 20 minute washout period (n = 7 Sed and 7 Ex); 4. Whole heart 
ischemia/reperfusion experiments (n=7 Sed and 7 Ex animals); 5. Whole-heart 
perfusion for 15 min (with no diamide) for ‘untreated controls’ (n = 6 Sed and 5 Ex 
animals), or 6: Isolated cardiac myocyte experiments (n=4 Sed and 4 Ex animals).  
Following each whole heart perfusion protocol, hearts were removed and the left 
ventricle frozen for further analysis. Each set of experiments is described in detail in 
Figure 6.   
 
Figure 6: Protocols used in this study 
  Baseline 200 µM Diamide until sustained arrhythmia 
Group 1 (N = 8 per group): 
  Baseline 39 minutes of 200 µM Diamide 
Group 2 (N = 8 Ex only): 
  Baseline 30 minutes 200 µM Diamide 
Group 3 (N = 7 per group): 
 20 minute Washout 
  Baseline 30 minutes Global Ischemia 
Group 4 (N = 7 per group): 
 30 minutes Reperfusion 
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Isolated Heart Perfusion 
 Twenty-four hours after the last bout of exercise (or handling control), rats were 
anesthetized using a ketamine/xylazine mixture (90 mg/kg ketamine, 10 mg/kg xylazine, 
i.p.).  Upon the absence of animal response reflexes, hearts were removed via midline 
thoracotomy, placed briefly in 0.9% saline (4˚C), and cannulated by the aorta on a 
modified Langendorff apparatus. Hearts were instrumented for the measurement of left 
ventricular function, coronary flow, and electrocardiogram as previously described (38, 
236).  Briefly, hearts were retrograde perfused with gassed (95%O2 5%CO2) Krebs 
buffer containing (mM) 118 NaCl, 24 NaHCO3, 4.8 KCl, 2 CaCl2, 1.2 MgSO4, 1.2 
KH2PO4, and 10 glucose (37⁰C). The calcium content in the experimental buffers is on 
the high end of the physiological range, but normoxic hearts perfused under these 
experimental conditions retain function for at least 90 minutes with no loss of function 
(41), suggesting that calcium overload in our preparation (perfusion time ~60 min) is 
minimal in non-stressed hearts.   A latex balloon (Harvard Apparatus) was inserted 
through the mitral valve into the left ventricle and inflated to a diastolic pressure of 4-7 
mmHg for measurement of left ventricular pressures. ECG leads were placed in the 
bath for volume-conducted ECGs.  Coronary flow was monitored throughout the 
protocol with a Transonic flow probe placed in series with the perfusion line proximal to 
the perfusion cannulas, and flow rates were normalized to heart wet weight. All 
measurements were recorded on a PowerLab System (A.D. Instruments) at a sampling 
rate of 1000Hz.  Data were stored on a personal computer and subsequently analyzed 
using Chart 7.0 software (A.D. Instruments).  
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Diamide Experiments 
Following instrumentation, 16 hearts (n = 8 Sed and 8 Ex) were allowed to 
equilibrate for 15 minutes and baseline values were recorded, after which the buffer was 
switched to Krebs buffer with the addition of 200µM diamide. Diamide perfusion was 
allowed to continue until the heart entered a sustained (greater than 10 seconds) 
ventricular arrhythmia. In a separate subset of Ex hearts (n = 8), diamide perfusion 
lasted 39 minutes, which was the average time it took for Sed hearts to go into an 
arrhythmia. 
To determine if Ex improved the ability of hearts to recover following diamide 
treatment, 14 hearts (n=7 per group) were perfused with diamide for 30 minutes. After 
the 30 minute diamide perfusion, the buffer was switched back to the diamide-free 
Kreb’s for a 20-minute washout period to determine the extent of recovery. The 
concentration of diamide used in this study has previously been shown to deplete the 
cardiac glutathione pool and induce cardiac arrhythmias (38). Immediately following 
perfusion, the left ventricle was isolated and frozen in liquid nitrogen for biochemical 
analysis.  
Ischemia/Reperfusion Experiments 
A subset of 14 hearts (n=7 and 7 for Sed and Ex groups, respectively) was 
subjected to 30 minutes of global no-flow ischemia by stopping flow to the heart. 
Following 30 minutes of ischemia, the static buffer was drained from the perfusion lines 
and flow was restored for 30 minutes. As with the other groups, the left ventricle was 
isolated and frozen at the end of reperfusion for biochemical studies.   
 39  
Arrhythmia Assessment 
Arrhythmias were scored in accordance with the Lambeth Conventions (263).  
Arrhythmias were scored for the diamide treatment and washout periods separately, 
and for the entire reperfusion period.  The scoring system used was: 0 = 0-49 premature 
ventricular beats; 1 = > 50 premature beats; 2 = at least 1 episode of VT (regardless of 
duration); 3 = at least one episode of VF (regardless of duration) and 4 = fatal event.  
Cardiac Myocyte Isolation 
Hearts from Sed and Ex animals (n=4 per group) were excised after anesthesia 
as described above and promptly placed on a retrograde perfusion cannula.  Isolated 
cardiac myocytes were prepared using methods similar to those previously described 
(37).  Briefly, the hearts received 5 minutes of perfusion with calcium-free Tyrode’s 
solution containing (in mM): 140 NaCl, 10 HEPES, 5 KCl, 1 MgCl2, and 10 Glucose (pH 
= 7.4, 37°C).  The solution was then switched to a digestion buffer consisting of 
Tyrode’s solution plus 25µg/mL Liberase DH (Roche) and 20µM CaCl2 for 22-26 
minutes. The heart was cut down and the left ventricle minced in digestion buffer in a 
heated (37°C) dissection dish. Chunks were gently aspirated with pipettes of increasing 
resistance (25mL, 10 mL, and 5mL serological pipettes) for 5 minutes.  The cell 
suspension solution was filtered through 0.25µm mesh and allowed to gravity precipitate 
for 12 minutes. Following gravity precipitation, cells were exposed to increasing 
amounts of calcium in Tyrode’s (50, 100, 200, 400 µM and 1 mM), each followed by a 
12 min gravity precipitation, before being put into Dulbecco’s Modification of Eagle’s 
Medium (DMEM) with 10% Fetal Bovine Serum. Once in DMEM, the cells were 
incubated (37°C, 5% CO2, balance room air) and used within 8 hours post-dispersion.  
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Cellular ROS Fluorescence Measurements 
At the time of each experiment, isolated myocytes were placed in Tyrode’s 
solution containing 1.8mM CaCl2, and cellular ROS production was measured with the 
fluorescent probe 5-(6)-chloromethyl-2,7-dichlorohydrofluorescein diacetate (CM-DCF, 
Invitrogen). CM-DCF fluorescence increases in proportion with cellular ROS production, 
specifically production of H2O2 and hydroxyl radical, but not superoxide (259).  
Ventricular cardiomyocytes from Sed and Ex animals were loaded with 500nM CM-DCF 
for 10 minutes and placed in a heated (37 ⁰C) flow-through perfusion chamber (Warner 
Instruments) housed on the stage of an inverted fluorescent microscope (Leica).  CM-
DCF fluorescence was evoked using light from a metal-halide lamp filtered to an 
excitation wavelength of 472nm (bandpass filter width 30nm), and emission was 
collected at 520nm (bandpass filter width 36nm).  Emitted light was captured with a 
CCD camera, and images were acquired on a personal computer.  To avoid 
photobleaching of the probe, sampling rate was set at 1 min intervals.  Our preliminary 
data indicated that this sampling rate and flourophore concentration led to stable 
recordings in normoxic (non-stressed) myocytes for up to 50 minutes (data not shown).  
After 5 minutes of baseline imaging, the solution was switched to Tyrode’s solution plus 
200 µM diamide. Fluorescence was monitored every minute for 40 minutes or until cell 
death occurred, whichever came first.  
Changes in fluorescence intensity were quantified for each time-point by 
subtracting the cell fluorescence (obtained via a region of interest drawn around the cell 
perimeter) from background fluorescence (obtained via a region of interest in an area 
adjacent to each myocyte).  To account for unequal flourophore loading across cells, 
each cellular fluorescence trace was normalized to baseline fluorescence intensity (Fo) 
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(before diamide) for each cell.  As expected, diamide treatment led to an increase in the 
CM-DCF signal over time, rapidly increasing after about 15 minutes of diamide 
treatment.  Because some of our myocytes died during diamide treatment (depicted in 
Figure 11D), we were not able to plot the average fluorescence intensity increase over 
the time of treatment (as cell death precludes accurate fluorescence measurements).  
Therefore, we quantified an ‘inflection point’, when the fluorescence signal significantly 
increased from baseline. We defined the inflection point as the time point when the 
fluorescence slope (using a linear fit) increased more than 3 times from the mean slope 
during the first 5 minutes of treatment. At the beginning and end of each experiment, a 
bright-field image of each cardiac myocyte was obtained using differential interference 
contrast, and these images are presented along with fluorescence traces for improved 
clarity.   
Myocardial Glutathione, Glutathione Peroxidase, and Glutathione Reductase  
Myocardial glutathione was assessed as described previously (38). Briefly, total 
glutathione (GSHt) and oxidized glutathione (GSSG) were determined using a 
commercially available kit (Oxis International). Final concentrations were normalized to 
protein content using a BCA Protein Assay (Thermo Scientific).  
For the determination of glutathione peroxidase (GPx) and glutathione reductase 
(GR) activities, 50-70 mg of frozen powdered tissue was homogenized in the presence 
of 0.3 mM 1-methyl-2-vinylpyridinium trifluoromethanesulfonate, and samples were 
diluted in ddH2O so that 1.5 mg protein per sample was loaded into a 96-well plate. 
Glutathione reductase was measured similar to the method of Carlberg and Mannervik 
(48). Briefly, samples were loaded in triplicate on a 96-well plate containing 1 mM 
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GSSG and 0.5 mM NADPH in TEE buffer (10 mM Tris, 1 mM EDTA, 1mM EGTA, pH 
7.4). Absorbance at 340nm was measured over 5 minutes and the rate of oxidation for 
1µM NADPH/min is equivalent to 1 U of GR activity. A similar method was used for 
measurement of glutathione peroxidase, as described previously (250). Samples were 
loaded into 96-well plate along with 1 mM GSH, 100 mU/ml glutathione reductase, 0.5 
mM NADPH, and tBOOH in TEE buffer. Absorbance at 340 nm was measured over 5 
minutes and the rate of NADPH oxidation per minute was used to calculate the GPx 
activity.  
Statistical Analysis 
All data are expressed as mean ± S.E.M. Comparisons for dichotomous 
variables between Sed and Ex were done using a Student’s t-test. Arrhythmia scores 
and glutathione content, between each group and baseline values, was analyzed with 
two-way ANOVA (group x treatment), followed by Newman-Keuls post-hoc tests. 
Between-group comparisons for incidence of ventricular fibrillation and fatal arrhythmias 
were made using a chi square test. Analysis of left ventricular developed pressure was 
determined via a two-factor (group x time) ANOVA with repeated-measures (time). 
Analysis of the Kaplan-Meier survival curve was done with a one-tailed Mantel-Cox test. 
For all comparisons, statistical significance was determined if P<0.05.  
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Results 
Animal Characteristics Following Exercise 
Morphological data 
from animals in the study are 
presented in Table 2.  
Consistent with our previous 
work (43), our short-term 
exercise protocol did not lead 
to significant differences in 
body, adrenal, or spleen 
weights. We observed 
significant hypertrophy of the heart 
following 10 days of exercise. 
Baseline hemodynamic values are 
presented in Table 3, and we found 
no differences in cardiac function 
between Sed and Ex hearts during 
baseline recordings.   
Incidence of Ventricular Arrhythmia Following Diamide Treatment 
The time to the first sustained arrhythmia during diamide treatment is presented 
in Figure 7. Ex hearts had a delayed onset of ventricular arrhythmia when compared to 
their Sed counterparts (P<0.05; Figure 7). A sustained arrhythmia was defined as any 
ventricular arrhythmia occurring with a duration ≥ 10 seconds. The average time for Sed  
Table 2: Morphological data from experimental animals. Data are 
expressed as mean ± s.e.m.  Abbreviations: HW, heart weight; BDW, 
body weight; LV, left ventricle. 
 Sed  Ex  P Value 
BDW (g) 220 ± 2 214 ± 6 0.441 
Left Adrenal (mg) 35 ± 8 38 ± 7 0.321 
Right Adrenal (mg) 34 ± 1 37 ± 8 0.929 
Spleen (mg) 561 ± 83 599 ± 92 0.608 
Heart Weight (mg) 858 ±25 954 ± 28 * 0.013 
LV Weight (mg) 503 ± 17 602 ± 16 * P<0.001 
HW/BDW * 1000 4.0 ± 0.1 4.4 ± 0.2 * 0.02 
Table 3:  Baseline hemodynamic variables for hearts in the 
study.  Data are expressed as mean ± s.e.m.  
 Sed Ex 
LVDP (mmHg) 116 ± 8 114 ± 6 
Coronary Flow (mL/min*g) 9.2 ± 1.2 10.0 ± 0.6 
Heart Rate (bpm) 301 ± 13 314 ± 7 
+dP/dt (mmHg/sec) 4312 ± 380 4728 ± 427 
-dP/dt (mmHg/sec) -2564 ± 240 -2903 ± 178 
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animals to enter an arrhythmia was 39 minutes, and it should be noted that not one 
animal in the Ex group had a time to arrhythmia less than 39 minutes. 
The extent and severity of 
cardiac arrhythmias for hearts in the 
group exposed to 30 minutes of 
diamide exposure and 20 minutes of 
washout are presented in Figure 8.  
As expected, during the shortened 
diamide treatment, the incidence and 
severity of arrhythmia was not 
significantly different between Sed 
and Ex.  However, during the 
washout period, hearts from the Ex 
group had a significantly lower 
incidence of arrhythmia, as reflected by a lower arrhythmia score and longer time until 
the first run of VT/VF during washout (P<0.05; Figure 8C and D). Ex significantly 
 
Figure 7: Exercise delays the onset of ventricular arrhythmias during sustained thiol oxidation. A. Representative left 
ventricular developed pressure (LVDP; black trace) and volume-conducted electrocardiogram (ECG; gray trace) 
recordings from a sedentary animal approximately 39 minutes into diamide treatment. The transition to ventricular 
arrhythmia and subsequent loss of pump function is noted with an arrow. B: Representative trace from an exercised 
animal during the same duration of diamide treatment as the sedentary trace. C Mean time to onset of ventricular 
arrhythmia following sustained diamide treatment; *, P<0.05 vs. Sed. N = 8 per group. Mean ± S.E.M.  
 
Figure 8: Ex decreases the severity of arrhythmias in the 
isolated rat heart exposed to reversible treatment with the thiol 
oxidant diamide (30 min), followed by a 30 minute washout 
period.  A: Arrhythmia scores (calculated from System A) 
between Sed and Ex animals during/after the diamide 
treatment. B: Arrhythmia scores (calculated from System B) 
between Sed and Ex animals during/after the diamide 
treatment.  C: Percentage of hearts in each group that 
experienced an episode of VF. D: Summary of hearts in each 
group that experienced a fatal (non-spontaneously reverting) 
ventricular arrhythmia; *, P<0.05 vs. Sed during diamide 
treatment; +, P<0.05 vs. Ex during diamide;  #, P<0.05 vs. Sed 
during washout.  N= 7 per group. Mean ± S.E.M.  
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decreased the number of hearts that had an episode of VF (P<0.05; Figure 8E), and 
lowered the incidence of non-reverting (fatal) arrhythmia at the end of the protocol 
(P<0.05; Figure 8F).  
Incidence of Arrhythmia Following Global Ischemia/Reperfusion 
Reperfusion arrhythmias in 
hearts exposed to 30 minutes of 
global ischemia/reperfusion are 
presented in Figure 9. During 
reperfusion, hearts from Ex animals 
had a significantly lower arrhythmia 
score (P<0.05; Figure 9A). Ex also 
significantly decreased the number 
of hearts that experienced an 
episode of VF (P<0.05; Figure 9B). 
The incidence of fatal arrhythmias was not significantly different between Sed and Ex 
animals, But none of the 7 Ex animals had a fatal arrhythmia, whereas 2 Sed animals 
were fatal at the end of the protocol (Figure 9 C; P=0.13). 
 
Figure 9: Incidence of reperfusion arrhythmias in hearts 
exposed to 30 minutes of global ischemia and 30 minutes of 
reperfusion. A: Arrhythmia scores (calculated from System A) 
for hearts 15 minutes into reperfusion. B: Arrhythmia scores 
(calculated from System B) for hearts 15 minutes into 
reperfusion. C. Summary of hearts in each group that 
experienced an episode of VF. D. Incidence of non-reverting 
(fatal) arrhythmia during reperfusion for hearts in the study.  *, 
P<0.05 vs. Sed. N = 7 per group. Mean ± S.E.M. 
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Left Ventricular Function 
 Left ventricular developed pressure 
(LVDP) data from the study where 
functional recovery was under 
investigation are presented in Figure 10. 
Diamide treatment induced a steady 
decline in the pressure developed in the 
left ventricle. This decrease in LVDP was 
significantly attenuated in the Ex group 
(P<0.05).  Developed pressure rebounded 
during the washout period in the Ex group and was significantly greater than the 
sedentary controls starting 11.5 minutes into the washout period and lasting throughout 
the remainder of the protocol (Figure 10; P<0.05).  In the group exposed to 
ischemia/reperfusion there was no statistically significant differences in recovery of LV 
function between Sed and Ex animals (LVDP at the end of reperfusion was 18 ± 3 and 
27 ± 4 mmHg, for Sed and Ex respectively; P=0.14). 
Cellular ROS Production 
Cellular ROS (specifically H2O2 and hydroxyl radical) production during diamide 
treatment was monitored in isolated ventricular myocytes with the flourophore CM-DCF, 
and representative images and traces are presented in Figure 11A and B.  Black and 
white images represent bright-field images of the myocyte at the beginning (left) and 
end (right) of each experiment.  The sudden increase in CM-DCF fluorescence after 
approximately 15 min of diamide has been previously observed in isolated cardiac 
 
Figure 10: Left ventricular developed pressure (LVDP) 
during diamide treatment and washout for Sed (black 
circles) and Ex (gray circles) groups. Hearts were 
perfused with 200 µM diamide for 30 minutes, followed 
by a 20 minute washout; *, P<0.05 Main effect; **, 
P<0.05 Bonferonni post hoc for time. N= 7 per group. 
Mean ± S.E.M. 
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myocytes (9), and is consistent with the concept of mitochondrial criticality (for review, 
see (8)).  This steep rise in H2O2 emission that preceded myocyte death was quantified 
using an inflection point, and the time to inflection was significantly delayed in Ex 
animals (Figure 11C; P <0.05).  As diamide exposure often led to cell death in some 
cells (depicted in the Sed representative image in Figure 11A), we plotted a Kaplan-
Meier survival curve for myocytes in the study (Figure 11D).  Myocytes from Ex animals 
displayed both a delay in the onset of cell death, as well as a decrease in the total 
number of cells that died following diamide treatment.  
 
Figure 11:  Ex delays the increase in ROS fluorescence and decreases cell death in isolated ventricular myocytes 
exposed to oxidative stress.  A: Representative images over time for Sed and Ex myocytes. Black and white 
pictures represent bright field images of myocytes at the beginning and end of each experiment, and fluorescence 
traces in between are fluorescence images from cells loaded with the ROS sensor CM-DCF.  B: Representative 
CM-DCF traces from Sed (black line) and Ex (gray line) myocytes. C: Average time to inflection for both groups. D: 
Survival curve for Sed (black) and Ex (gray); *, P<0.05 for Sed versus Ex myocyte survival. N = 18 (from 4 animals) 
for Sed and 25 (from 4 animals) for Ex. Mean ± S.E.M.  
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Myocardial Glutathione, Glutathione Peroxidase, and Glutathione Reductase  
Myocardial glutathione content data are presented in Figure 12. At baseline, 
there was no significant difference between Sed and Ex in total glutathione (GSHt), 
oxidized glutathione (GSSG), or the reduced/oxidized glutathione ratio (GSH/GSSG) 
(Figure 12A, B, and C respectively). In the Sed and Ex groups that were allowed to 
enter a sustained arrhythmia, perfusion with diamide led to a significant decrease in 
GSH/GSSG. In the Ex group perfused with diamide for only 39 minutes, there was also 
a significant decline in GSH/GSSG from baseline. However, this group had a 
significantly higher GSH/GSSG ratio than both the Sed and Ex groups that were 
allowed to continue until an arrhythmia occurred (Figure 12C).  
GSHt in the Sed group decreased significantly in the washout and reperfusion 
groups, but did not significantly change in the Ex group (Figure 12A; P<0.05). GSSG 
levels increased in both the Ex and Sed groups entering a sustained arrhythmia as well 
as the Ex group receiving 39 minutes of diamide perfusion (Figure 12B).  
GSH/GSSG declined significantly following washout in the Sed hearts perfused 
with diamide for 30 minutes, but was not significantly decreased in the Ex group (Figure 
 
Figure 12: Myocardial content of total glutathione (GSHt), oxidized glutathione (GSSG), and ratio of reduced to 
oxidized glutathione (GSH/GSSG). All tissue collected immediately after the completion of each perfusion protocol. A: 
total glutathione (GSHt) content. B: oxidized glutathione (GSSG) content. C: ratio of reduced to oxidized glutathione 
(GSH/GSSG) in hearts. *, P<0.05 vs. Sed at Baseline; #, P<0.05 vs. Ex Baseline; +, P<0.05 vs. Ex until arrhythmia; 
Mean ± S.E.M.   
 49  
12C). In the I/R group Sed hearts showed a decline in the ratio of GSH/GSSG, but 
remained unaltered in the exercise group (Figure 12C).  
 
Glutathione reductase 
activities from diamide only 
treated hearts are presented 
in Figure 13. In hearts 
perfused until a ventricular 
arrhythmia occurred, there 
was no significant difference 
between Sed and Ex animals.  
If the perfusion was limited to 
39 minutes in the Ex group, there was a significant preservation in glutathione 
reductase activity versus both the Sed and Ex groups (P<0.05; Figure 13). 
Enzyme activities from 
untreated hearts are presented in 
Figure 14. There were no 
differences in the activity of 
myocardial GPx between Sed and 
Ex. On the other hand, GR activity 
was significantly greater in the 
hearts of Ex animals than in Sed 
animals (Figure 14; P<0.05).  
  
 
Figure 13: Glutathione reductase (GR) activity in hearts exposed to 
sustained thiol oxidation. Hearts were cut down after the onset of 
ventricular arrhythmia (time-points noted in Figure 1) and analyzed for 
GR activity.  A subset of exercised hearts was cut down at the mean 
arrhythmia onset time for sedentary hearts (39 minutes).   *, P<0.05 vs. 
Sed; #, P<0.05 vs. Ex.  N = 8 per group. Mean ± S.E.M. 
 
Figure 14: Basal changes in cardiac glutathione reductase (GR) 
and glutathione peroxidase (GPx) enzyme activity for sedentary 
(Sed) and exercise trained (Ex) hearts.  *, P<0.05.  N = 6 for Sed 
and 5 for Ex. Mean ± S.E.M. 
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Discussion 
This study was conducted to determine if short-term exercise (Ex) protected 
hearts against arrhythmias during conditions of oxidative stress.  Our results indicate 
that Ex delays the onset and decreases the incidence and severity of ventricular 
arrhythmias following thiol oxidation and ischemia, and that augmented ROS-buffering 
capacity by the cardiac glutathione system is associated with this anti-arrhythmic 
phenotype.  To the best of our knowledge, several aspects of this work represent novel 
findings.  First, we demonstrated that Ex confers an anti-arrhythmic phenotype in 
isolated female hearts exposed to two different oxidative challenges.  Second, we 
observed that isolated myocytes from Ex animals display slower rises in cellular H2O2 
levels and lower incidence of cell death during oxidative stress than sedentary cells. 
Third, Ex led to better maintenance of GSH/GSSG following thiol oxidation or ischemia.  
Finally, increased glutathione reductase activity is directly related to the preservation of 
the glutathione redox couple in a more reduced state during sustained oxidative stress. 
Taken together our results indicate that short-term exercise augments the ability of 
female hearts to replenish cardiac GSH through glutathione reductase reaction during 
an oxidative challenge leading to decreased incidence and severity of arrhythmias, 
improved cardiac function, and delayed cellular death.   
Exercise-induced Protection Against Arrhythmia 
Our observation that Ex reduced fatal ventricular arrhythmias confirms findings in 
both human epidemiological studies (103) and previous reports using animal models 
(105, 118, 194, 220).  Using an isolated heart model, we found that Ex reduced the 
incidence and severity of ventricular tachycardia/fibrillation (VT/VF) either after 
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overwhelming cellular anti-oxidant defenses with the thiol-oxidant diamide or following 
global ischemia/reperfusion. These findings are in agreement with other studies where 
exercise protected against arrhythmias induced by in vivo ischemia/reperfusion (105, 
118, 220) or ectopic ventricular pacing protocols (194).  By using the isolated female rat 
heart, we were able to corroborate earlier work (in male animals) (194) showing that 
exercise induces intrinsic adaptations in the heart that protect against arrhythmia.  
In this study, we found that Ex delays the onset of ventricular arrhythmia during 
conditions of sustained oxidative stress. A likely explanation for this time-dependency is 
that exercise, like other preconditioning stimuli, delays the onset of injury but loses 
efficacy with prolonged insult (88, 186, 203, 273).  Interestingly, when the diamide insult 
was shortened to investigate the ability of Ex hearts to recover we found that this 
protection from arrhythmias persisted, possibly due to the preservation of glutathione 
reductase reaction’s ability to re-reduce oxidized glutathione. This Ex-induced decrease 
in arrhythmias also allowed for better recovery of cardiac function after diamide 
(consistent with several ischemia/reperfusion studies (35, 41, 157, 279)).  
Role of the Cardiac Glutathione System in Arrhythmias 
Glutathione is the largest capacity thiol buffer in the heart (229), and 
uncompensated oxidation of reduced glutathione (GSH) to oxidized glutathione (GSSG) 
can induce catastrophic ventricular arrhythmias (for review see (8, 46)).  In this study, 
we used two different models of glutathione oxidation to evoke arrhythmia: chemical 
oxidation of the glutathione pool with diamide, and ischemia/reperfusion.  As expected, 
each intervention reduced both total glutathione and the reduced/oxidized glutathione 
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(GSH/GSSG) ratio in Sed animals (See Figure 12). These findings are in agreement 
with previous studies where ischemia/reperfusion depleted cardiac glutathione (154) 
and lowered GSH/GSSG (51, 210, 253, 265).  In sedentary controls, the extent of 
glutathione depletion/oxidation with diamide was similar to what we observed following 
reperfusion (Figure 12) and the incidence and severity of arrhythmias was also 
comparable between these groups (see Figure 8 and Figure 9).   
During conditions of oxidative stress, cardiac action potentials can become 
heterogeneous subsequent to the opening of sarcolemmal ATP-sensitive potassium 
(KATP) channels (3, 199).  Oscillatory KATP currents occur in phase with fluctuations in 
mitochondrial membrane potential (∆Ψ m) when cellular/mitochondrial anti-oxidants 
become overwhelmed (10).  Collapses in ∆Ψ m following GSH oxidation have been 
observed in intact hearts (38, 237) and isolated myocytes (9). This collapse in 
bioenergetics induced by GSH oxidation was associated with the onset of ventricular 
arrhythmias (38).  Pharmacological treatments that maintain GSH/GSSG ratios during 
oxidative challenge sustain ∆Ψ m (9, 94) and decrease cardiac arrhythmias (38).  Of 
notable translational interest, improving the GSH buffering capacity with the glutathione 
precursor N-acetylcysteine was also effective in preventing arrhythmias in humans 
undergoing cardiac surgery (204).   
Exercise-induced Preservation of Cell Viability and GSH/GSSG  
We show for the first time that Ex leads to a phenotype that is resistant to 
arrhythmias through the preservation of GSH/GSSG. This is evidenced by the fact that 
both GSH/GSSG and glutathione reductase activity are higher in our Ex group 
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subjected to only 39 minutes of diamide treatment when compared to the Sed group. 
This exercise-induced delay against GSH oxidation and subsequent arrhythmias in 
intact hearts was associated with improved cellular H2O2 buffering and significantly 
greater resistance to cell death during thiol-oxidation in isolated cardiac myocytes.  To 
the best of our knowledge, this study is the first observation that exercise-induced 
protection against sustained oxidative stress has been shown in viable ventricular 
cardiomyocytes.  During oxidative stress, there is a sharp increase in ROS emission 
observed when ‘mitochondrial criticality’ is reached (8).  We observed a spike in cellular 
ROS along the same time-scale as previous work (10), and found that the time until this 
ROS surge was significantly prolonged in myocytes from Ex animals.  
The depletion in cardiac GSH was attenuated in Ex hearts in the washout and I/R 
groups (Figure 12A). These results support our hypothesis that Ex delays the ROS 
surge because of preserved cardiac H2O2 scavenging capacity.  Short-term exercise did 
not alter basal GSH/GSSG ratio or the GPx enzyme activity, consistent with several 
other reports (106, 220, 241).  However, following either challenge, GSH/GSSG was 
much better maintained in Ex hearts. This suggests that the preservation of GSH in a 
more reduced state is more important in delaying H2O2 accumulation than scavenging 
of H2O2 by the GPx reaction. 
Exercise-induced sustainment in GSH/GSSG was likely due to increased activity 
of glutathione reductase, which has been previously reported in female hearts after 
exercise (268).  As the enzyme responsible for reducing GSSG back to GSH, these 
data suggest that it is not the ROS-scavenging ability of the glutathione system that is 
 54  
protective following exercise (as there is no increase in GPx activity; see Figure 14), but 
rather the ability of the heart to replenish GSH.  Given that the de novo synthesis of 
glutathione is very low in the heart (99), and that GSSG is released from the heart 
during reperfusion (254) the importance of GSH replenishment is obligatory for the 
heart’s ability to withstand a sustained oxidative challenge.  Of interest, the ability to 
regenerate GSH is enhanced by a polarized ∆Ψ m to support NADPH regeneration by 
the mitochondrial NADH/NADPH transhydrogenase (229).  While the high GSH/GSSG 
ratio that we observed in Ex hearts exposed to oxidative stress would likely be 
associated with a higher ∆Ψ m (9), future experiments will provide insight into additive 
effects of enhanced glutathione reductase and better maintenance of ∆Ψm after Ex.   
Although there may be variability across animal species, it is interesting to note 
that a GSH/GSSG ratio < 50 has been implicated as a threshold for the opening of the 
mitochondrial permeability transition pore (9), which induces necrotic and apoptotic cell 
death (102).  Our observation that GSH/GSSG in animals that were perfused with 
diamide until an arrhythmia occurred had values below 50 while the Ex group that 
received only 39 minutes of perfusion remained higher than 50 and was absent of any 
sustained ventricular arrhythmias is of particular interest. Furthermore, Ex animals 
receiving only 30 minutes of diamide followed by a washout, exhibited a decrease in 
arrhythmia severity, improved cardiac function, and GSH/GSSG values above 50 in our 
Ex group versus lower values in their Sed counterparts.  This preservation of 
GSH/GSSG may explain the delayed production of ROS and lower propensity for cell 
death in Ex myocytes. While speculative, this would be in line with previous studies 
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indicating that Ex elicits a phenotype characterized by reduced opening of the 
mitochondrial permeability transition pore (134).   
Our finding that Ex improves the ROS-scavenging ability of the heart through 
improved GSH replenishment compliments several studies examining other ROS-
scavenging mechanisms within the myocardium.   Using anti-sense oligonucleotides, 
Hamilton et al. (105) showed a role for manganese superoxide dismutase (MnSOD) in 
exercise-induced protection against arrhythmia, and a recent paper by Quindry’s group 
also showed upregulated MnSOD activity following short-term exercise training that 
associated with the anti-arrhythmic phenotype (220).   In both of these studies, there 
was no clear exercise-induced upregulation in either GPx or catalase, the major routes 
for the conversion of H2O2 to water.  Given that the product of enzymatic superoxide 
dismutation is H2O2, the lack of heightened capacity to break down the H2O2 
(augmented by upregulated MnSOD) left several unanswered questions.  In this study, 
we offer a putative explanation that the ability of the Ex heart to scavenge H2O2 lies not 
in improved scavenging by GPx (seen herein and also in both (105, 220)), but by 
augmented replenishment of GSH through glutathione reductase.  Indeed, other studies 
have shown that GR activity increased (in liver) proportionally with the amount of 
exercise (269). Although there are obvious limitations to this speculation, including sex-
specific differences in MnSOD (44) and GPx (268),  this viewpoint could provide a 
consensus into how Ex augments ROS-scavenging capacity from superoxide 
production through the complete conversion to water.   Clearly, future experiments are 
warranted to support this notion.   
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Limitations 
 This study used 10 days of exercise to elicit a cardioprotective phenotype. Our 
previous work showed that 10 days of exercise in female rats evoked some early 
adaptations to training (such as increased skeletal citrate synthase activity), while 
minimizing markers of systemic stress (43). This model of exercise may be independent 
of changes seen with classical ‘exercise training’, where the exercise stimulus is carried 
out for many months and more robust training adaptations (such as resting bradycardia) 
are observed.  Also, we obtained a volume-conducted ECG signal by placing the leads 
directly into the bath surrounding the heart. Volume-conducted ECGs are generally 
more variable than leads placed on the surface of the heart and thus did not allow for 
direct comparison of electrical vector between groups. We used 2.0 mM CaCl2 in our 
Kreb’s Henseleit buffer. This level of calcium may be considered hypercontractile, 
however all groups were exposed to the same levels of calcium. 
Conclusions 
In this study, Ex induced intrinsic changes to the female heart that reduced the 
susceptibility to arrhythmias during two distinct oxidative challenges.  This 
cardioprotection was observed in intact hearts and isolated cardiac myocytes, and 
involved augmented ROS buffering capacity after exercise. Specifically, the ability to 
maintain a reduced glutathione environment through heightened glutathione reductase 
activity may be the underlying mechanism by which Ex confers protection. Our findings 
contribute to a growing body of literature describing the cardioprotective effects of 
exercise, a very inexpensive and widely available preventative strategy.  Future studies 
examining pharmacological strategies designed to improve glutathione replenishment 
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have enormous potential as prophylactic therapies seeking to abrogate fatal ventricular 
arrhythmias. 
  
Chapter 4: Exercise-induced preconditioning relies on NAD(P)H oxidase, and not 
mitochondrial, derived reactive oxygen species in isolated rat hearts. 
 
Introduction 
Cardiovascular disease constitutes a significant amount of the mortality within the 
United States, with myocardial ischemia accounting for the largest portion of these 
deaths. Despite the fact that prompt reperfusion remains the best treatment for 
myocardial ischemia, restoration of coronary flow is associated with further cell death, 
likely due to an increase in reactive oxygen species at the onset of reperfusion (210, 
254, 283). An improved capacity to buffer reactive oxygen species is centrally involved 
in exercise-induced protection from ischemia/reperfusion (I/R) injury (87). 
Under pathological conditions, reactive oxygen species (ROS) are generally 
thought to exacerbate the insult. However, evidence is emerging the ROS signaling 
actually may play an important role in cell life as well as death (for review see (101, 
116)). ROS have been implicated in the cardioprotective signaling cascade underlying 
ischemic preconditioning (79, 161, 247), heat stress (13), anesthesia (34, 66), and 
angiotensin II treatment (138). Interestingly, ROS signaling appears to be upstream of 
protective signaling mediated by PKC, implying that ROS may be one of the first steps 
of the signal transduction cascade leading to cardioprotection (79). 
Exercise has been shown to be a potent and sustainable form of cardiac 
preconditioning by us and others (41, 44, 104, 251). In our previous work we 
demonstrated that prior exercise led to an increase in the ability of glutathione to buffer 
ROS and decrease ventricular arrhythmias (90). This was associated with an increase 
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in glutathione reductase (GR) activity and better maintenance of reduced to oxidized 
glutathione (GSH:GSSG). Similarly others have shown that increased antioxidant 
capacity following an exercise regimen is associated with a cardioprotective phenotype 
(105, 271), although the signaling processes involved in antioxidant upregulation are not 
fully understood.  
A modest increase in ROS may play a vital role in cellular events leading to 
exercise preconditioning, and several studies suggest that ROS-scavengers may 
actually prevent the cardioprotective adaptations after exercise. During exercise ROS 
production has been shown to increase (for review see (123, 214)) and this transient 
redox shift can be blocked with administration of an antioxidant (5, 192).  Using the 
NAD(P)H oxidase inhibitor apocynin, Sanchez and colleagues found that inhibiting the 
formation of NAD(P)H oxidase blunts the cardioprotective effects of exercise and 
tachycardia (227). Use of the general antioxidant N-2-mercaptopropionyl glycine (MPG) 
has also been shown to blunt the beneficial effects of exercise on myocardial infarction 
(5) and cardiovascular function (192). However, neither of these studies directly 
compared if the site of ROS generation are important for the signaling involved in 
exercise-induced preconditioning.  
The purpose of this study was to investigate the importance and origin of ROS 
generated during exercise on exercise-induced preconditioning. Using Bendavia, a 
novel peptide that has been shown to decrease mitochondrial ROS (57, 248, 281), and 
apocynin (an inhibitor of NAD(P)H oxidase formation) we investigated two major 
sources of ROS generation within the myocardium. Use of Bendavia in an animal model 
of diabetes has previously been shown by our lab to be protective (235). Herein we find 
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that administration of Bendavia just prior to exercise did not blunt the protection, but 
administration of apocynin abolished the protective effects of exercise. Our data 
suggest that during exercise a transient increase in the oxidative burden occurs, 
increasing GR activity.  This study is the first to directly investigate the 
compartmentalization of ROS generation in exercise. Furthermore, this study provides 
novel insight into how increased oxidative stress during an exercise bout can lead to 
post-translational modifications of GR. 
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Methods 
Animals 
All experiments were conducted in accordance with guidelines established by the 
Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85–23, revised 
1996), and with prior approval by East Carolina University’s Animal Care and Use 
Committee. Female Sprague-Dawley rats (150-250g) were housed on a 12:12 hour 
light-dark cycle with free access to food and water. A total of 94 animals were used in 
this study. 
Exercise Protocol 
Rats were exercised daily as described previously (89). Briefly, rats were given a 
3 day acclimation period on the treadmill. Ex animals then received 10 consecutive days 
of treadmill running for 60 minutes per day at 15 m/min for 15 minutes, 30 m/min for 30 
minutes, and 15 m/min for 15 minutes. Animals that did not run were gently prodded or 
received a mild shock.  
MTP-131 and Apocynin Injections  
 Rats were randomly assigned to receive an injection (i.p.) of either 1.5 mg/kg 
MTP-131 (n=7/group for Sed and Ex), 5 mg/kg apocynin (n=8 and 12 for Sed and Ex 
respectively), or 0.9% saline (n= n=12/group for Sed and Ex).  The injection was given 
ten minutes prior to each bout of exercise or handling control.  
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Isolated Heart Experiments 
Twenty four hours after the last bout of exercise rats were injected with 
ketamine/xylazine (90 mg/kg ketamine, 10 mg/kg xylazine, i.p.) and upon the absence 
of reflexes the hearts removed via midline thoracotomy and retrograde perfused on the 
cannula of a modified Langendorff apparatus as described previously (38, 236). 
Following a 15 minute baseline period global, no-flow, ischemia was induced for 25 
minutes. After 25 minutes, the static buffer was drained from the lines and flow was re-
established for two hours. Immediately following two hours of reperfusion the left 
ventricle was isolated and stained for infarct via TTC staining  as described previously 
(236). In a separate subgroup of animals hearts were perfused for 10 minutes before 
being snap frozen for subsequent biochemical analysis (n=4/group for Sed, Ex, and Ex 
+ Apocynin). 
Glutathione Reductase Inhibition 
 In another subset of hearts, carmustine (BCNU) was used in the isolated heart 
model described above to inhibit glutathione reductase activity. Following a 10 minute 
baseline period the buffer was switched to a Kreb’s buffer with 150 µM BCNU for 5 
minutes before global ischemia induction (n=6/group for Sed, Sed + BCNU, Ex, and Ex 
+ BCNU) and continued throughout the reperfusion period.  
Arrhythmia Assessment 
 Arrhythmias were scored as described previously (90) based on the 
electrocardiogram signal according to the Lambeth Conventions (63, 263). The 
incidence of ventricular fibrillation (VF) and fatal arrhythmias was noted for each group. 
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Myocardial Glutathione Content 
 Glutathione content was measured as described previously (38, 89). To assess 
the amount of glutathione oxidation that occurs during exercise animals were trained as 
normal and immediately following the last bout animals were anaesthetized and left 
ventricle snap frozen (n=4/group for Sed, Ex, and Ex + Apo). 
Glutathione Reductase Activity 
Glutathione reductase activity was measured in tissue homogenates as 
described previously (89). To determine the redox sensitivity of glutathione reductase 
within cardiac tissue a subset of experiments were carried out in which tissue 
homogenates were incubated with DTT (2mM) or diamide (200 µM) at 4⁰C for 20 
minutes prior to testing the activity.  
Immunoblot Analysis  
 Left ventricle homogenates were subjected to SDS-PAGE and subsequent 
transfer to a nitrocellulose membrane. Membranes were blocked for 1 hour at room 
temperature with Tris-buffered saline containing 0.1% Tween and 4% bovine serum 
albumin. Following blocking the membrane was incubated with an antibody for GR 
(1:1000; Invitrogen) overnight at 4°C. The membrane was then washed and incubated 
with an IR-Dye-conjugated secondary antibody (LiCor Biosciences). Membranes were 
scanned and quantified using the Odyssey Infrared Imaging system (LiCor 
Biosciences).  
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Statistical Analysis 
All data are presented as mean ± S.E.M. A two-way ANOVA (training x 
treatment), followed by Newman-Keuls post-hoc test was used for all analysis. 
Between-group comparisons for the incidence of ventricular fibrillation and fatal 
arrhythmias were made using a chi square test. For all comparisons, statistical 
significance was determined when P<0.05.  
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Results 
Animal Morphology and Baseline Characteristics 
 Rat morphological data is presented in Table 4. No differences were observed in 
body weight between groups. Furthermore, no indices of stress (as assessed by splenic 
atrophy or adrenal hypertrophy) were seen. However, there was a trend towards cardiac 
hypertrophy in our Ex animals following 10 days of exercise (P=0.07). 
Table 4: Morphological Data from animals in this study. Data presented as mean ± S.E.M. 
 
Sed/Saline Sed/Bendavia Sed/Apocynin Ex/Saline Ex/Bendavia Ex/Apocynin 
BDW (g) 234±5 242±7 220±3 247±7 243±8 235±7 
Spleen 
(mg) 
610±23 614±31 653±28 641±28 629±27 639±40 
L. Adrenal 
(mg) 
31±2 32±2 29±1 34±2 34±2 30±2 
HW/tibia 
(mg/mm) 
30±1 28±1 26±1 32±1 30±1 30±1 
 
Myocardial Infarction 
 Infarct size is presented in Figure 15. As expected, our Ex group had a significant 
reduction in infarct size (53 ± 3 vs. 40 ± 1% for Sed and Ex respectively; P < 0.05). 
Treatment with Bendavia had no effect on infarct size in our Ex group (42 ± 4%; P > 
0.05), but treatment with apocynin abolished the protective effects of exercise (53 ± 2%; 
P < 0.05 vs. Ex/Saline). In our Sed animals apocynin treatment had no effect on 
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myocardial infarction (55 ± 3%; P > 0.05), but Bendavia treatment significantly 
decreased the size of infarction (41 ± 3%; P <  
0.05 vs. Sed/Saline). 
 
 
Figure 15: Exercise-induced preconditioning abolished with apocynin treatment. * P<0.05 vs. Sed, # 
P<0.05 vs. Ex, + P<0.05 vs. Sed  and  MTP, @ P<0.05 vs. Ex and MTP. Mean ± S.E.M. 
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Glutathione Reductase Expression and Activity 
 Corroborating our previous work 
(89) Ex animals had increased GR 
activity (20.3 ± 1.3 vs. 49.9 ± 7.5 
mU/mg for Sed and Ex respectively; P 
< 0.05; Figure 16). This increase in 
activity was abolished in Ex animals 
treated with apocynin (26.4 ± 8.2  
mU/mg; P < 0.05). If Ex samples were 
treated with DTT, a thiol reductant, activity was reduced (26.3 ± 10.3 mU/mg; Figure 
17). Furthermore, if Sed samples were treated with diamide, a thiol oxidant, GR activity  
was significantly increased (57.3 ± 6.2 mU/mg; P < 0.05). No difference was seen 
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Figure 16: Inhibiting NAD(P)H oxidase generated 
ROS prior to exercise blunts increases in glutathione 
reductase activity. * P<0.05 vs. Sed, # P<0.05 vs. Ex 
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Figure 17: Redox modification of GR activity in 
Sed and Ex left ventricular homogenates. * P<0.05 
vs. Sed. 
Figure 18: No differences in GR protein expression 
between groups. 
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between groups in the expression of GR protein (P > 0.05; Figure 18).  
Glutathione Reductase Inhibition 
 Inhibition of glutathione reductase with the pharmacological inhibitor BCNU 
abolished the protective effects of Ex from myocardial infarction (57 ± 1; P < 0.05; 
Figure 19A). Perfusion with BCNU also abolished the protection of exercise against 
ventricular arrhythmias (Figure 19B) 
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Figure 19: GR inhibition abolishes exercise-induced preconditioning from myocardial infarction and 
ventricular arrhythmias. Infarct size (A)  and arrhythmia (B) data from isolated hearts perfused with BCNU 
*, P<0.05 vs. Sed; #, P<0.05 vs. ; Data presented as mean ± S.E.M. 
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Discussion 
Main Findings 
In this study we investigated if ROS produced during exercise act as signaling 
molecules that lead to exercise-induced preconditioning and if the site of this ROS 
generation plays a role. The major finding of this study is that ROS generated through 
NAD(P)H oxidase, and not within the mitochondria, act as signaling molecules involved 
in increasing the activity of glutathione reductase. We found that during exercise the 
oxidative burden on the cell transiently increases and may shift the oxidative state of 
GR, increasing its activity. Confirming the importance of GSH replenishment in 
exercise-induced preconditioning, we showed that pharmacological inhibition of GR 
abolished the beneficial effects of exercise. 
This study is important in establishing that ROS can act as signaling molecules 
under physiological conditions and that GSH replenishment through the GR reaction are 
important steps in exercise-induced cardioprotection. To our knowledge this is the first 
study to investigate if the origin of ROS (i.e. mitochondrial vs. cytosolic) plays a role in 
exercise-induced preconditioning. Interestingly, a recent study found that cytosolic ROS, 
and not mitochondrial, may contribute to cardiac hypertrophy in a glucose transporter 
knockout mouse (158). Further investigations into the origin of ROS and their role in 
physiology/pathophysiology will help establish their role response to various stressors 
and may alter the way we view ROS. 
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The Role of GSH in Cardiac Health 
During a bout of exercise reactive oxygen species are generated which lead to a 
transient oxidative shift in cellular thiols and in this study we establish that these ROS 
are generated through NAD(P)H oxidase and not the mitochondria. It is important to 
note that this transient increase in oxidative stress is protective, whereas others have 
found that when ROS are constitutively high some of the effects of exercise training are 
absent (223). The ability to maintain a high reduced to oxidized GSH:GSSG ratio is 
important for buffering ROS in the heart and is linked to improved cardiac function (38, 
46). Herein we found that an improved ability to maintain GSH may be a requisite for 
exercise-induced preconditioning. This corroborates our previous work where we 
showed the Ex animals had an increase in GR activity which was associated with an 
improved ability to maintain GSH in a reduced state, a decrease in ROS accumulation, 
and a lower incidence of fatal ventricular arrhythmias (89).   
Under physiological conditions, the heart’s ROS production is countered by 
sufficient antioxidant defenses. However, during pathological conditions ROS 
production exceeds the intrinsic antioxidant defenses and leads to cell death (11) (for 
example, ROS generation is elevated in early reperfusion (30, 283, 284)) and an ability 
to decrease this oxidative burden has been associated with improved cardiovascular 
health. Improved ROS scavenging following exercise training is well established in the 
literature (for review see (87)), but the role of the glutathione system in exercise-induced 
preconditioning remains unclear (131, 221, 241). This study helps establish that 
increased GR activity and maintenance of GSH:GSSG is important to the beneficial 
effects of exercise. 
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Redox Modification of Glutathione Reductase 
Since there is little de novo synthesis of GSH in the heart (99) the ability to 
replenish GSH is of significant importance. GSH represents the largest capacity thiol 
buffer in the heart (229) and is known to exert a significant effect on mitochondrial 
function (9, 237) and improving the heart’s ability to maintain GSH in its reduced state is 
an area that warrants further study. Fortunately, the reduction of GSSG by GR is 
kinetically more favorable that its other fates with the rate of the GR reaction 
approximately 20 times higher than its utilization or loss from the cell (18, 58, 202). 
The activity of GR has been shown to be affected by temperature, pH, and the 
redox status of the cell (211). Importantly, Edwards et al. found that GR does not exist 
in either a phosphorylated or carboxylated form (83), suggesting that post-translational 
modification of GR is primarily due to redox modification (95, 173, 211). In support of 
this, GR activity seems to be inversely proportional to the concentration of GSH (58). In 
mammals, where pH and temperature are held relatively constant under physiological 
conditions, redox modification of GR may be a pathway by which the heart increases its 
ability to replenish GSH under conditions of oxidative stress. In this study we found that 
Ex significantly increased GR activity and this increase in activity could be blunted if left 
ventricle homogenates from Ex animals were incubated with the thiol reductant, DTT 
(Figure 17). Similar to others (173), we also found that GR activity was significantly 
increased in our Sed group if samples were incubated with the thiol oxidant diamide, 
suggesting that redox modification of GR does occur within cardiac tissue. Although 
speculative, these data also seem to suggest that Ex animals have significantly more 
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oxidation of GR than Sed counterparts and future studies will be needed to validate this 
hypothesis.   
Physiological Role for NAD(P)H Generated ROS 
In this study we investigated the two major sites of ROS production within cardiac 
tissue: the mitochondria and NAD(P)H oxidase and found that NAD(P)H oxidase 
generated ROS are potent signaling molecules in exercise-induce preconditioning. In 
cardiac tissue NAD(P)H oxidase exist in two isoforms, NOX2 and NOX4 (47) and 
appears to be located in T-tubules, in close proximity to the sarcoplasmic reticulum (SR)  
(115, 277). An interesting observation is that NOX4 may generate ROS within a cellular 
compartment that is not readily accessible to current probes for superoxide, but once it 
is converted to hydrogen peroxide it is easily detected (76, 233). ROS produced in close 
proximity to the SR may play a role in modification of the ryanodine receptor and 
increasing calcium release (20, 115). Although speculative, ROS generated through 
NAD(P)H oxidase may provide an alternative mechanism to increase intracellular 
calcium during a bout of exercise and this physiological role for ROS generated within 
the cytosol (vs. the mitochondria) may explain their importance in exercise-induced 
preconditioning.  
Conclusions 
The results of this study include several novel findings that are important to the 
field of exercise-induced preconditioning. First, ROS generated through NAD(P)H 
oxidase, and not within the mitochondria, act as signaling molecules in the 
cardioprotective pathway. Second, an ability to increase GR activity seems to be a 
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requisite for decreasing cellular injury. Third, this study establishes that transient 
increases in ROS production occur during exercise and shift GSH:GSSG to a more 
oxidized state. This decreased ratio of GSH:GSSG may in turn act as a mechanism by 
which thiols on GR are modified and activity is increased. 
  
Chapter 5: Reduction of ischemia/reperfusion injury with Bendavia, a novel 
mitochondrial-targeting cytoprotective peptide.  
 
Introduction 
Early and successful myocardial reperfusion with primary percutaneous coronary 
intervention remains the most effective strategy for reducing the size of a myocardial 
infarct and improving clinical outcome. Reperfusion injury remains a major issue in 
patients who receive percutaneous coronary intervention, thrombolysis or have 
spontaneous reperfusion for ST-segment myocardial infarction. Given that long-term 
prognosis has been linked to both size of infarction(112, 114, 178), strategies aimed to 
decrease infarct size have significant clinical potential.  
Reactive oxygen species are centrally involved in the development of myocardial 
infarction.  Augmented production of reactive oxygen species (ROS) during early 
reperfusion contributes to myocyte death (175, 228).  Elevated ROS increases the open 
probability of the mitochondrial permeability transition pore (PTP)(102), which is 
followed by bioenergetic collapse and ultimately cell death.  Given that mitochondrial 
ROS production is high in early reperfusion, therapies that directly (and effectively) 
target mitochondrial ROS production are ideal in this setting. Recently, a novel class of 
cell permeable small peptides has been developed that selectively target mitochondria. 
The Szeto-Schiller (SS) peptides are relatively small (<10 amino acids), water soluble 
molecules that contain a similar structural motif of alternating basic (Arg, Lys) and 
aromatic (Phe, Tyr, Dmt (2’6’-dimethyltyosine)) residues which allows them to freely 
cross cell membranes (despite a 3+ net charge at physiological pH)(280).  Studies with 
fluorescent and radiolabeled SS peptides indicate that they localize to mitochondria and 
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concentrate at the inner mitochondrial membrane (IMM) (281). One particular peptide, 
Bendavia (also called SS-31) has been shown to significantly reduce ROS levels (248) 
and protected hearts from injury in a rodent model of ischemia/reperfusion(56).   
The purpose of the present study was to determine whether the mitochondrial-
targeting cytoprotective peptide Bendavia could protect the myocardium from 
reperfusion injury.  We discovered that Bendavia decreases infarct size in an isolated 
heart model. This was corroborated with work done in isolated cardiomyocytes showing 
that Bendavia may abolish cell death due to ROS accumulation during early reperfusion 
and lead to better maintenance of bioenergetics.  
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Methods 
 The animals used in these studies were maintained in accordance with the 
policies and guidelines of the Position of the American Heart Association on Research 
Animal Use (American Heart Association, 1985) and the Guide for Care and Use of 
Laboratory Animals (1996).  Protocols received prior approval by The Institutional 
Animal Care and Use Committee (East Carolina University).  
Ischemia/Reperfusion Injury in Guinea Pigs 
Adult male guinea pigs (200-300g) were anesthetized with a ketamine/xylazine 
cocktail (85/15 mg/kg, respectively; i.p.). Upon the absence of reflexes to ensure a deep 
plane of anesthesia, hearts were excised via midline thoracotomy and immersed in ice-
cold saline. Guinea pig hearts were placed on a modified Langendorff apparatus and 
instrumented for the observation of electromechanical function as previously described 
(37, 38, 89). After a 10-minute equilibration period, hearts were divided into the 
following treatment groups: 1. Control followed by global ischemia/reperfusion (I/R); 2. 
Administration of 1nM Bendavia in the perfusate beginning 10 minutes before index 
ischemia and for the entire reperfusion; 3. Post-ischemic administration of 1nM 
Bendavia for the duration of reperfusion; 4. Post-ischemia administration of 0.2µM 
cyclosporine A. Hearts were exposed to global no-flow ischemia by stopping perfusion 
for 20 minutes. At the end of the 120-minute reperfusion period, infarct size and 
arrhythmia scores were assessed as previously described (37, 38, 236). 
Myocyte Hypoxia/Reoxygenation Experiments 
Guinea pig left ventricular myocytes were isolated by enzymatic digestion for 
hypoxia/reoxygenation studies using our established protocols(89). Isolated primary 
cardiomyocytes were incubated (95% O2 balance room air, 37 C) for 2-8 hours post-
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dispersion.  For the drug treatment groups, myocytes were either incubated for 10 
minutes with 1nM Bendavia prior to being placed in the perfusion chamber (Bendavia 
group), or received no drug treatment (Control group).  Cells were placed into a custom-
built perfusion chamber housed on the stage of an inverted fluorescence microscope for 
the study of cell survival during cellular hypoxia/reoxygenation. For each myocyte 
experiment, cells were allowed to settle on the glass coverslips for at least 20 minutes 
before the initiation of perfusion. More information on the construction of the perfusion 
chamber is provided in the Methods Supplement.   
Myocytes were superfused for a 5 minute baseline period with Tyrode’s solution 
containing (in mM): 140 NaCl, 10 HEPES, 5 KCl, 1 MgCl2, 1.8 CaCl2, and 10 glucose 
(pH = 7.4, 37°C), delivered via an in-line solution heater a rate of 1.0-1.2mL/min. 
Myocytes were paced (4ms duration, 1Hz frequency, 10V amplitude) for the duration of 
the hypoxia-reoxygenation protocol.  Our decision to pace during hypoxia is based on 
observations indicating that guinea pig myocardium maintains electrical activity through 
20 minutes of ischemia(3). After 5 minutes of baseline perfusion, the solution was 
switched to Tyrode’s solution gassed with 100% argon (hypoxia solution) for 20 
minutes. Following 20 minutes of perfusion with hypoxia solution, the superfusate was 
switched back to normoxic Tyrode’s to initiate reoxygenation. Cells were reoxygenated 
for 30 minutes or until cell death, whichever came first. When appropriate, the time of 
myocyte death during hypoxia/reoxygenation was noted by complete transition from 
rod-shaped to rounded, necrotic cell morphology. Differential interference contrast 
images of the myocytes were obtained at the beginning and end of each experiment.   
Subsets of myocytes that underwent hypoxia-reoxygenation were loaded with 
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one of two fluorescent probes to monitor either cellular ROS levels or mitochondrial 
membrane potential (∆Ψ m) during the protocol (described below).  Another cohort of 
cells was exposed to hypoxia/reoxygenation with no fluorescent probe to determine if 
the flourophores themselves influenced cell survival.  Since the different flourophores 
did not influence the proclivity to cell death during the protocol (when compared to 
unloaded cells), the data were pooled for the survival plot to include all cells exposed to 
hypoxia/reoxygenation.   
Myocyte ROS Levels During Hypoxia/Reoxygenation 
For the determination of cellular ROS production, guinea pig ventricular 
cardiomyocytes were loaded with 500 nM of the fluorescent ROS probe 5-(6)-
chloromethyl-2,7-dichlorohydrofluorescein diacetate (CM-DCF, Invitrogen) for 10 
minutes in the incubator prior to imaging as described previously (89). CM-DCF 
fluorescence intensity was captured every 30 seconds throughout the 
hypoxia/reoxygenation experiments.  
Mitochondrial Membrane Potential (∆Ψm) During Hypoxia/Reoxygenation 
Separate experiments were conducted to determine the influence of Bendavia on 
∆Ψm during cellular hypoxia/reoxygenation. Isolated guinea pig ventricular myocytes 
were loaded with the ∆Ψm sensor tetramethylrhodamine, methyl ester (TMRM; 25nM, 
‘non-quench mode’) for 10 minutes prior to imaging.  TMRM fluorescence intensity was 
captured every 60 seconds throughout hypoxia and reoxygenation or until cell death, 
whichever came first.  
Statistical Analyses 
The myocyte survival curve was analyzed using a Logrank (Mantel-Cox) test 
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based on the a prioi hypothesis that Bendavia would improve cell survival. Infarct Size 
and Bendavia Uptake data for the Guinea Pig hearts were analyzed using an ANOVA 
followed by Newman-Keuls Post-Hoc tests for between-group comparisons. For all 
comparisons, significance was noted if P<0.05.   
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Results 
Effect of Bendavia on Ischemia/Reperfusion Injury  
The effect of Bendavia on 
infarct size is presented in Figure 
20.  Following the 
ischemia/reperfusion protocol, 
untreated (control) guinea pig 
hearts had infarct sizes of 50 ± 4 % 
of the area at risk (AAR; n = 14, 
Figure 1). Administration of 1nM 
Bendavia, either before ischemia (n 
= 9) or at the onset of reperfusion 
only (n = 9), significantly reduced 
infarct size to 30 ± 5 and 31 ± 6 % 
AAR, respectively (p<0.05 versus control, ANOVA). Treatment with 0.2µM CsA also 
significantly reduced infarct size to 33 ± 5 % of the AAR (p<0.05 versus control, 
ANOVA; n = 8). There were no differences in infarct size among treatment groups.  
Effects of Bendavia on Post-Ischemia Hemodynamic Recovery and Arrhythmia 
Bendavia had no major effects on the recovery of cardiac electromechanical 
function after ischemia/reperfusion. Neither the incidence of arrhythmia nor the extent of 
recovery of left ventricular function was influenced by Bendavia treatment. Arrhythmia 
scores for the 2h reperfusion period were 4.9 ± 0.4 in the control group (n = 14). 
Administration of Bendavia, either before ischemia or at the onset of reperfusion, had no 
 
Figure 20: Infarct size in isolated guinea pig hearts exposed to 
20 minutes of ischemia and 2 hours of reperfusion. Whole time = 
compound administered both before and after ischemia; @ 
reperfusion = compound administered only during reperfusion; P 
< 0.05 versus control (ANOVA). 
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effect on arrhythmia scores (5.7 ± 0.7 and 4.4 ± 0.4, respectively, n = 9 and 9, 
respectively; P > 0.05, ANOVA). CsA treatment also had no significant effect on the 
incidence of arrhythmia (arrhythmia score of 4.0 ± 0.5, n = 8; P > 0.05, ANOVA). Left 
ventricular developed pressure at the end of the 2 hour protocol was 22 ± 5 mmHg in 
the control group (n = 14), and 24 ± 6 mmHg when Bendavia was administered before 
and after ischemia (n = 9). Administration of Bendavia or CsA at the onset of 
reperfusion also had no effect on recovery of developed pressure (39 ± 5 and 34 ± 6 
mmHg, n = 9 and 8, respectively; P > 0.05, ANOVA).  
Guinea Pig Myocyte Survival During Hypoxia/Reoxygenation 
In this study, a total of 78 guinea pig cardiac myocytes were exposed to cellular 
hypoxia/reoxygenation. Since 
cells died during both the hypoxic 
and reoxygenation periods, a cell 
survival plot is presented in Figure 
21. A total of 43 cells were 
exposed to hypoxia/reoxygenation 
under control (no drug) conditions, 
with another 35 cells that were 
treated with 1nM Bendavia. At the 
end of the 20 minute hypoxia 
period, 65% (28 of 43 total) of 
control cells and 74% (26 of 35 
total) of Bendavia-treated cells were still alive (no drug effect during hypoxia, P>0.05, 
 
Figure 21: Bendavia significantly abolished ROS-dependent cell 
death, but the extent of cell death during hypoxia as well as ROS-
independent cell death during reperfusion was similar to control.  
Survival plot for myocytes in the study exposed to hypoxia and 
reoxygenation. Each cell death event is noted as a downward step 
in the survival curve. *, P<0.05 versus control for the reoxygenation 
period. 
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Mantel-Cox test).  Bendavia specifically prevented death associated with reoxygenation. 
Following reoxygenation there was a significant decrease in cell death evoked by 
Bendavia. Of the cells that were alive at the onset of reoxygenation, only 54% of control 
cells survived until the end of reoxygenation, compared to 85% of cells that were treated 
with Bendavia (P<0.05 for survival during reoxygenation).  
Role of Mitochondrial ROS in Cell Death 
 A subset of 
myocytes (n = 35 
total) exposed to 
hypoxia/ 
reoxygenation was 
loaded with the ROS 
sensor CM-DCF 
during the protocol to 
monitor ROS 
production with (n=18) 
or without (n=17) 
Bendavia pre-
treatment. 
Representative 
images and traces of 
cells are presented in 
Figure 22. The vast 
A. 
 
B.     
 
Figure 22: Cellular ROS production during hypoxia/reoxygenation. A: 
Representative fluorescence images of cardiac ventricular myocytes loaded with 
the ROS sensor CM-DCF.  ROS bursts during reoxygenation preceded cell death, 
and Bendavia treatment prevented ROS-induced cell death. B: Representative 
fluorescence intensity traces for cells in the study.  CM-DCF fluorescence is 
normalized to the basal fluorescence (Fo) for each cell at the end of hypoxia.   
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majority of cell death in 
the control group was 
preceded by a burst of 
ROS during the 
reoxygenation period. 
The ROS-dependent 
cell death was 
completely prevented 
in myocytes treated 
with Bendavia (Figure 
23). ROS-independent 
cell death during hypoxia or reoxygenation was similar between the control and 
Bendavia-treated groups.  
Maintenance of Mitochondrial Membrane Potential (∆Ψm) 
 A different subset of myocytes (n = 37 total) were exposed to 
hypoxia/reoxygenation while loaded with the ∆Ψ m indicator TMRM (presented in Figure 
24).  Myocytes treated with Bendavia were protected against cell death during 
reoxygenation, and specifically against cell death that was preceded by a collapse of 
∆Ψm, suggesting that the treatment prevented the opening of the mitochondrial 
permeability transition pore and subsequent loss of ∆Ψm.  
  
 
Figure 23: Contribution of ROS bursts to myocyte death during 
hypoxia/reoxygenation. 
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A. 
 
 
B.  
 
Figure 24: Mitochondrial membrane potential (∆Ψm) in myocytes during cellular hypoxia/reoxygenation. A. 
Representative fluorescence images of myocytes loaded with the ∆Ψm sensor TMRM.  ∆Ψm collapse often preceded 
cell death, and treatment with Bendavia improved the capacity to maintain ∆Ψm.  B. Representative fluorescence 
intensity traces for cells in the study.     
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Discussion 
Key Findings 
 
 The present studies show that Bendavia, administered after the onset of 
ischemia, demonstrated cardioprotective effects. Bendavia reduced myocardial infarct 
size in isolated guinea pig hearts exposed to ischemia/reperfusion.  Bursts of reactive 
oxygen species were blunted by Bendavia, resulting in better maintenance of 
mitochondrial energetics and reduced cell death during reoxygenation. 
 Numerous agents have been tested as adjunctive therapy for reperfusion injury 
in the setting of acute myocardial infarction. At the present time early reperfusion via 
thrombolytic therapy or percutaneous coronary intervention (including percutaneous 
transluminal coronary angioplasty) are the only accepted definitive therapies for acute 
myocardial infarction(231). Early reperfusion limits myocardial infarct size and improves 
survival. However, not all patients receive early coronary artery reperfusion, and at the 
time of reperfusion some degree of injury may occur due to reperfusion itself.  
Cardioprotection at Reperfusion: Salvaging Cells that are Salvageable 
Cell death during ischemia and reperfusion is multi-factorial, and is generally 
attributed to a combination of necrosis, apoptosis, and autophagy (185).  Although a 
matter of some debate, necrotic cell death is probably the predominant cause of death 
in ischemic myocardium (17).  During early ischemia, insufficient electron flow down the 
mitochondrial electron transport chain shifts cellular ATP production away from 
oxidative phosphorylation. Cells increase rates of glycogen breakdown and transition to 
anaerobic glycolysis, and contraction rapidly ceases as intracellular pH decreases. As 
ischemia progresses, declining ATP levels lead to cellular sodium and calcium overload 
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(Figure 4).  Necrotic cell death ensues, exacerbated by the development of ischemic 
contracture which strains cellular structural integrity. 
While reperfusion is requisite to salvage tissue, prompt reperfusion can also 
injure cells that are hovering between life and death. Elevated intracellular levels of 
calcium, sodium, and inorganic phosphate, an alkaline shift towards physiological pH, 
and production of reactive oxygen species are all noted in early reperfusion (185).  
These factors promote the opening of energy-dissipating channels in the inner 
mitochondrial membrane.  In particular, the open probability of both the mitochondrial 
permeability transition pore (reviewed in (102)) and the inner membrane anion channel 
(reviewed in (46)) is greatly enhanced by reactive oxygen species. Oxidant-induced 
pore/channel opening collapses mitochondrial membrane potential (∆Ψm), leading to 
cessation of ATP production and ultimately cell death.   
The Mitochondria as a Therapeutic Target 
In the clinical realm, heightened reactive oxygen species production is implicated 
in the development of reperfusion injury (46). There is obviously a great deal of interest 
in decreasing reperfusion injury with compounds that scavenging reactive intermediates 
and/or directly blocking the permeability transition pore.  Among the candidate radical 
scavengers tested to date, early efforts focused primarily on superoxide dismutase 
mimetics and catalase.  These approaches reduced infarct size in some (27, 53, 136, 
141) (but not all (217)) animal studies.  Despite promising results in animal studies, 
these strategies do not appear to translate to beneficial effects in clinical trials (85, 256). 
The reasons for the lack of translation to the clinic have been described in detail 
elsewhere (80, 139), but likely involve cell permeability concerns and findings that non-
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specific radical scavengers must be used in very high doses to see efficacy.  Further, 
superoxide dismutase mimetics scavenge only superoxide anion, while a significant 
portion of tissue injury may arise from radical-independent redox signaling (i.e. oxidative 
shifts in intracellular thiols)(128).   
Direct permeability transition pore blockers have recently shown potential in 
reducing reperfusion injury in animal and human studies. CsA, which inhibits the 
association of cyclophilin D with the mitochondrial permeability transition pore, has been 
shown to reduce cardiac ischemia/reperfusion injury ((81, 234) and Figure 20).  In a 
recent small clinical trial (212), cyclosporine given at the time of percutaneous coronary 
intervention significantly reduced infarct size in humans (assessed using both MRI and 
enzymatic markers in serum), corroborating previous data from animal studies. A 
multicenter clinical trial is currently underway in Europe, investigating cyclosporine in a 
larger population of myocardial infarct patients. While these early results are promising, 
the use of cyclosporine may be confounded by a narrow therapeutic window (189), non-
specific effects on other cellular cyclophilins/calcineurin (262), and reports of 
cyclosporine-induced vasoconstriction(26).  
Reduction of Infarction with Bendavia 
There is a clear need for cytoprotective compounds that freely cross the 
sarcolemma, are effective across low doses, and target specifically to the region within 
the cell where sites of oxidant production is high (specifically, the mitochondria).  Drs. 
Hazel H. Szeto and Peter W. Schiller developed a new class of peptides that 
concentrate within mitochondria and reduce intracellular ROS generation(249).  
Bendavia (D-Arg- Dmt-Lys-Phe-NH2; analogous to SS-31 in the literature) is a 
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tetrapeptide that crosses cell membranes and targets to the inner mitochondrial 
membrane.  From a therapeutic standpoint, a promising property of Bendavia is that 
mitochondrial accumulation of Bendavia appears to be independent of the ∆Ψ m.  ∆Ψ m 
collapses during ischemia and the recovery of ∆Ψ m at reperfusion is very 
heterogeneous in the myocardium (174, 237).  Treatment strategies that require ∆Ψ m 
for mitochondrial delivery (such as anti-oxidants conjugated to triphenylphosphonium 
cations, i.e. MitoQ, MitoE, MitoSOD (238)) may only be targeting cells that are already 
on their way to recovery.  In our study, myocardial uptake of Bendavia was observed 
even in early reperfusion when ∆Ψ m may be compromised, consistent with studies in 
isolated cells where accumulation was not markedly affected by chemical uncouplers of 
mitochondria (281).   Furthermore, the ∆Ψm -depolarizing effects of compounds tethered 
to triphenylphosphonium makes them self-limiting and translates to a very narrow 
therapeutic window of efficacy (248). Bendavia treatment has no noticeable effect on 
basal ∆Ψ m when assessed by either TMRM fluorescence (281) or 
triphenylphosphonium uptake (Unpublished observations), allowing for a very wide 
therapeutic range and cardioprotection at/below nanomolar concentrations ((281) and 
herein). 
In this study, we show for the first time that Bendavia treatment reduces cellular 
reactive oxygen species generation and helped sustain ∆Ψ m in primary cardiac 
myocytes exposed to hypoxia/reoxygenation.  In particular, Bendavia reduced oxidant-
dependent cell death during the reoxygenation period, yet had no effect on myocyte 
survival during hypoxia.  This finding supports our hypothesis that this compound is 
most effective when production of reactive oxygen species is high.  In our cellular 
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studies, it seems plausible that Bendavia reactive oxygen species sustained ∆Ψ m by 
reducing the open probability of energy-dissipating ion channels in the inner membrane 
(such as the permeability transition pore and/or the inner membrane anion channel). 
Our myocyte data corroborate previous work in cell culture models, where Bendavia 
lowered the levels of reactive oxygen species and promoted cellular survival in neuronal 
cells exposed to t-butylhydroperoxide (281).  Further studies are needed to determine 
the exact mechanism by which this peptide reduces reactive oxygen species levels and 
stabilizes mitochondrial energetics.  
The cardioprotection that we observed in isolated guinea pig cells translated to 
infarct-size reduction in the isolated heart.  Importantly, this protection was observed if 
Bendavia was given after the onset of ischemia.  These data support the concept that 
damage to the mitochondria at the time of reperfusion is a therapeutic target. These 
studies confirm a previous study showing that the agent reduced infarct size in an acute 
rat model of myocardial infarction (56). However, in Cho’s study, Bendavia was 
administered both prior to coronary occlusion as well as prior to reperfusion. In all of the 
models presented here, Bendavia worked when given after coronary artery occlusion, 
including studies in which the drug was given just at reperfusion, supporting the concept 
that it reduced reperfusion injury.  
Summary 
 In conclusion, the mitochondria-targeting agent, Bendavia, demonstrated 
cardioprotective properties in in vitro and in vivo experimental models when 
administered prior to reperfusion. It protected cardiomyocytes, it limited myocardial 
infarct size, and for the first time was shown to reduce limit no reflow. Bendavia 
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protected cells from reactive oxygen species damage and preserved mitochondrial 
potential. Bendavia is an attractive candidate for clinical studies in cardiac 
ischemia/reperfusion injury. 
  
Chapter 6: Integrated discussion 
Major Findings 
 The overriding hypothesis of this work is that ischemia/reperfusion injury is 
characterized by mitochondrial overload of ROS that collapses mitochondrial energetics 
and leads to cellular injury. These studies help to establish the importance of cardiac 
glutathione in decreasing this ROS burden. Furthermore, they establish that maintaining 
reduced glutathione through the glutathione reductase reaction may be an important 
factor in exercise-induced preconditioning. Finally, treatment of cardiac tissue with 
Bendavia led to decreased ROS accumulation and decreased myocardial infarction. 
Taken together the work presented in this dissertation provide novel insights into 
physiological and pharmacological approaches that decrease oxidative stress and cell 
death during ischemia/reperfusion injury. 
 In Chapter 3 I showed that Ex led to a phenotype that maintained GSH in a 
reduced state during conditions of thiol oxidation and ischemia/reperfusion. This was 
likely mediated by an intrinsic increase in the GR activity. Chapter 4 goes one step 
further by showing that pharmacological inhibition of GR abolishes protection. 
Furthermore, it showed that ROS generated through NAD(P)H oxidase act as signaling 
molecules that may post-translationally modify GR, thereby increasing its activity. 
Lastly, Chapter 5 investigated a pharmacological approach aimed at decreasing 
myocardial infarction. We found that Bendavia decreased mitochondrial ROS 
accumulation, preserved mitochondrial energetics, and led to decreased cellular injury. 
Given that we found that cytosolic ROS may be involved in preconditioning signaling 
invoked by Ex and that the role for mitochondrial ROS may be limited to the pathology 
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associated with reperfusion injury, these opposing functions may be part of the reason 
antioxidant treatments have translated poorly into the clinic (1, 167, 274). 
 One interesting finding of this study is that exercise-induced preconditioning and 
Bendavia treatment may converge on the same mechanism. Although speculative, this 
convergence may occur at the ability to buffer mitochondrial ROS during reperfusion. 
This is substantiated by several findings: 1) in isolated hearts there was no difference in 
the extent of protection if Bendavia was given either before ischemia or at the onset of 
reperfusion (Figure 20); 2) administration of Bendavia via i.p. injection for 10 days led to 
increased protection in our Sed animals (Figure 15); and 3) There was no additive 
effects on exercise with Bendavia treatment. Since both exercise and Bendavia were 
shown to decrease ROS accumulation (Figure 11 and Figure 22 respectively) this is 
likely the site of convergence, and may help explain why there was no additive effects 
on Ex. 
Future Directions 
 The studies presented within this dissertation describe how glutathione regulation 
may be an underlying factor involved in the preconditioning effects of exercise. Chapter 
4 establishes that ROS generated through NAD(P)H oxidase during exercise act as 
signaling molecules that increase GR activity. Although the data presented within 
strongly suggest that GR activity is vital to the cardioprotective phenotype, the post-
translational modifications of GR that lead to this increase in activity need to be further 
elucidated.  
Figure 17 shows that post-translational modification do occur through redox 
sensitive mechanisms, most probably through thiol-thiol interactions. This is consistent 
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with the literature where it has been shown that GR lacks candidate sites for  
phosphorylation or carboxylation (83) and that GR activity is related to glutathione 
concentrations and the general redox status of the cell (58, 95, 173, 211). Directly 
demonstrating that Ex leads to a decrease in the amount of free thiols on GR would 
help to definitively determine if this is how ROS signaling modifies the GR protein.  
Another interesting study would be to investigate the redox status of GSH in the 
cardiac tissue immediately following exercise. This would give us an index of the extent 
of oxidative shift that occurs during exercise, and if this is blunted when cytosolic ROS 
formation is inhibited. With this knowledge we could directly investigate if physiological 
shifts in the oxidative state of the glutathione couple could directly affect the activity of 
GR in vitro.  
 The final chapter of this work utilized a pharmacologic approach to decrease 
oxidative stress during ischemia/reperfusion. Although the results are promising for this 
compound, there are several questions left to answer. First, we saw that 
cardiomyocytes treated with Bendavia were better able to maintain mitochondrial 
energetics during hypoxia/reoxygenation (Figure 24). Since we think that this compound 
is decreasing mitochondrial ROS, it would be interesting to see if cardiomyocytes 
treated with Bendavia were less susceptible to permeability transition during 
hypoxia/reoxygenation. Another important area left open to further study is if the timing 
of Bendavia administration affects ischemia/reperfusion injury. Given that we saw the 
same extent of protection regardless of whether hearts were treated before ischemia or 
at the onset of reperfusion (Figure 20). It would be interesting to see if Bendavia has a 
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“therapeutic window” wherein it has to be administered after the re-establishment of 
coronary flow. 
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Appendix B: Effects of rat estrous cycle on myocardial ischemia/reperfusion injury  
Introduction 
Epidemiological evidence suggests that women are less at risk for a 
cardiovascular event prior to undergoing menopause (258). Recent evidence has 
implicated that this may be associated with increased circulating levels of estrogen 
(107). The effect of menstrual cycle on cardiovascular disease has been less studied in 
humans than in animals, probably due to the rare nature of these events in a younger 
population. In fact a recent study found that cardiovascular events in menstruating 
women accounts for only 1% of all events (184). However, there is evidence that the 
phase of the menstrual cycle can have profound effects on cardiovascular function. 
Moran et al. have shown that blood pressure and heart rate can vary between phases 
(181). It’s also been shown that women early in the menstrual cycle have more risk for 
angina (135), supraventricular tachycardia (188, 225), and exercise induced ST 
depression (163).  SVT episodes were also linked to decreased levels of circulating 
estradiol and increased levels of progesterone (225). Interestingly, females who were 
irregular in their cycle are more susceptible to future coronary heart disease (23, 239) 
that can be extended to postmenopausal years (15). Since animal research is a potent 
tool for investigating cardiovascular disease, further investigation is warranted into the 
effects that the estrous cycle may have on cardiovascular health. 
In animal models the cardioprotective phenotype of premenopausal females has 
been shown in mice, rats, rabbits and dogs (44, 64, 144, 152, 264). Although several 
mechanisms have been suggested for the possible underlying mechanism, none of 
these studies have delved into the changes that may occur to cardiac tissue during 
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specific phases of the estrous cycle. Unfortunately, to date nobody has examined if the 
effects of fluctuating hormone levels during the estrous cycle have any effect on cardiac 
tissue and most of what has been shown is the effects of sex hormones on vascular 
function (258). 
Unlike humans, rodents do not undergo a menstrual phase where the uterine 
lining sloughs off and is expelled through the vagina, but rather the lining degenerates 
back to the normal size in an estrous cycle (166). The estrous cycle (in rats) is defined 
by four separate phases: proestrus, estrus, metestrus, and diestrus. Proestrus is 
characterized by increasing levels of estrogen. At the end of proestrus, ovulation 
(signaled by luteinizing hormone) occurs and marks the beginning of the estrus phase. 
During metestrus and diestrus the uterine lining degenerates back to normal and the 
cycle starts again (166, 230).         
Since no study to date has investigated the role of estrous cycle phase on the rat 
heart, this study was performed to see if the effects of fluctuating hormones during the 
estrous cycle have acute changes on cardiac tissue. By utilizing both in vivo and ex vivo 
models we will also be able to discern if the effects of hormones have acute affects or 
are limited to the circulation. Here we find that the estrous phase does not have any 
effect on the level of myocardial infarction in rat hearts. The level of myocardial 
infarction was not correlated with serum levels of 17-β estradiol or progesterone adding 
to our conclusion that estrous cycle phase has no bearing on the extent of injury 
following ischemia/reperfusion. No differences in the severity of arrhythmias or 
incidence of ventricular fibrillation (VF) with cycle phase were observed.  
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Methods 
Animals 
Female Sprague-Dawley rats were obtained and kept on a 12:12 light dark cycle 
with access to food and water ad libitum. Rats were ordered so that they were over 50 
days old at the onset of experiments.  Typically female rats will automatically begin 
cycling immediately after the vaginal orifice opens at around 32-36 days (96, 166). To 
ensure a more regular cycle, Rats were housed in a room with at least one male rat for 
the duration of the study (96).Research was performed in an AAALAC-accredited facility 
and animals use adhered to the principles stated in the Guide for the Care and Use of 
Laboratory Animals (NIH Publication No. 85–23, revised 1996) and was approved by 
the East Carolina University IACUC. 
Vaginal Cytology Examination 
To evaluate estrous stage in the rats, vaginal cytology was performed daily at 
0900.   A sterile cotton-tipped swab moistened with sterile saline was inserted into the 
rat’s vaginal opening.  The swab was rotated gently against the vaginal wall and 
removed.   The swab was immediately rolled onto a glass slide, then the smear was 
fixed by the use of a spray fixative (Safetex-Cytology Spray Fixative,  Andwin Scientific, 
Woodland Hills, CA) and then stained with Dip Quick Stain Preparation (JorVet, 
Loveland, CO).  Each slide was dipped into the three solutions 10 times, as this was 
determined to produce optimal staining quality. On the day of experiments, vaginal 
cytology was performed just prior to heart excision in order to get the most accurate 
reading of the phase each animal was in. Slides were analyzed by 2 independent 
reviewers for estrous phase. In the event that the 2 reviewers could not agree a third 
independent reviewer was brought in.  Estrous stage was determined using the 
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following criteria: Estrous > 75% squamous cells; Proestrus, mix of basal and squamous 
cells accounting for over 80% of slide; Diestrus > 80% neutrophils; Metestrus, mix of all 
three cell types. To confirm that our rats were cycling vaginal swabs were taken from 
animals every morning over the course of 8 days and they all displayed either a 4 day or 
5 day cycle (Figure 25). 
 
Figure 25: Representative images from vaginal cytology for Proestrus (A), Estrus (B), Metestrus (C), and Diestrus 
(D) phases of the estrous cycle. (E) Daily changes in the phase of estrous in our animals. 
In Vivo Preparation 
 Animals were anesthetized with ketamine/xylazine (90 mg/kg ketamine, 10 mg/kg 
xylazine, i.p.) and upon the absence of reflexes a midline tracheotomy was performed. 
The animals were intubated with PE-90 tubing and mechanically ventilated. 
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Supplemental injections of ketamine/xylazine (i.p.) were given as needed to maintain a 
surgical plane of anesthesia. A circulating water heating pad was use to maintain body 
temperature at 37°C.  
Animals were given a 10-min equilibration period on the ventilator. Then the 
thorax was opened via a left parasternal incision, the pericardium was removed from the 
heart, and the left anterior descending coronary artery (LAD) was ligated by using a 
reversible snare applied 4 mm distal to the origin between the conus arteriosus and the 
left atrium. LAD occlusion was confirmed with the appearance of myocardial cyanosis 
distal to the occlusion. Following 25 min of occlusion, the ligature was released, and 
reperfusion ensued for 2 h. To minimize desiccation the chest walls were approximated 
with Parafilm.  
To determine the area at risk (AAR) was risk the LAD was religated at the 
original point of occlusion immediately following 2 hours of reperfusion and a 1% Evans 
blue solution was infused through the aorta. After Evans blue staining, infarct size was 
determined via TTC staining as described previously (236) and expressed as a percent 
of the AAR. 
Ex Vivo Preparation 
Animals were injected with ketamine/xylazine mix (90 mg/kg ketamine, 10 mg/kg 
xylazine, i.p.) and upon the absence of reflexes the hearts removed via midline 
thoracotomy and retrograde perfused on the cannula of a modified Langendorff 
apparatus as described previously (38, 236). Following a 5 minute baseline period 
global, no-flow, ischemia was for 25 minutes. After 25 minutes flow was re-established 
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and reperfusion ensued for two hours. Immediately following reperfusion the left 
ventricle was isolated and stained for infarct via TTC staining as described above. 
Assessment of Arrhythmias 
Arrhythmias were scored as described previously and in accordance with the 
Lambeth Conventions (38, 263) from the ECG signal as follows: 0 = 0 – 49 premature 
ventricular beats; 1 = 50-499 premature ventricular beats; 2 = > 500 premature 
ventricular beats and/or 1 episode of spontaneously reverting ventricular tachycardia 
(VT) or fibrillation (VF) less than 30 sec in total duration; 3 = > 1 episode of reverting 
VT/VF that is < 60 sec total duration; 4 = >1 episode of reverting VT/VF that was 61 to 
119 seconds in total duration; 5 = VT/VF that is > 119 seconds in combined duration; 
6 = fatal (non-reverting) VT/VF that began > 15 min into treatment; 7 = fatal VT/VF that 
began between 4 minutes and 15 minutes min into treatment; 8 = fatal VT/VF that 
began between 1 and 4 minutes into treatment; 9 = fatal VT/VF that began within the 
first 59 seconds of treatment. 
Hormone Concentrations 
 Rat serum was collected from the body cavity immediately following heart 
excision. Levels of 17-β estradiol and progesterone were determined using a 
commercially available kit (Cayman Chemicals, Ann Arbor, MI).  
Statistical Analysis 
Analysis was done with either GraphPad (Prism) or SPSS software. One way 
ANOVA with Tukey’s post hoc test.  
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Results 
Baseline Characteristics 
  
 
 
 
 
 
 
Animal morphological data and baseline cardiac function (Langendorff prep) data are 
presented in Table 5. No significant differences were observed in animal body weight or 
heart weight across the phases of estrous. Furthermore, there were no differences in 
baseline left ventricular developed pressure (LVDP), coronary flow, or heart rate. 
Infarct Size 
Infarct size data are presented in Figure 26. There were no differences observed 
in the infarcted area of the tissue based on the phase of the estrous cycle in isolated 
hearts(Proestrus, 42 ± 6%; Estrus, 49 ± 4%; Metestrus, 40 ± 9%; Diestrus, 47 ± 9%; 
P=0.77; Figure 26A). Furthermore no differences were seen between phases for the in 
vivo preparation (Proestrus, 32 ± 6%; Estrus, 29 ± 8%; Metestrus, 28 ± 4%; Diestrus, 34 
± 5%; P=0.87; Figure 26B). There was also no correlation observed between the levels 
of circulating estradiol or progesterone at the time of heart excision and infarct size 
(Figure 26A and B respectively). 
 
 
 
Proestrus Estrus Metestrus Diestrus 
Body Weight (g) 204 ± 2 200 ± 4 205 ± 4 201 ± 4 
Heart Weight (g) 0.93 ± 0.03 0.99 ± 0.04 0.95 ± 0.03 1.00 ± 0.03 
LVDP (mmHg) 117.6 ± 0.5 107.0 ± 0.6 124.1 ± 0.4 127.7 ± 0.5 
Heart Rate (bpm) 233 ± 3 187 ± 3 193 ± 2 209 ± 2 
Coronary Flow (mL/min/g) 11.73 ± 0.05 10.05 ± 0.07 10.48 ± .04 11.06 ± 0.06 
 
Table 5: Baseline characteristic of animals in this study. 
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Figure 26: No difference in infarct size between the phases of the estrous cycle. Data from the ex vivo (A) and 
in vivo (B) hearts. There was also no correlation between infarct size and serum levels of estradiol (C) or 
progesterone (D) in isolated rat hearts. 
Arrhythmias 
Arrhythmias were scored for the first 15 minutes of reperfusion in isolated hearts. 
There were no differences observed in the severity of arrhythmias (as evident from our 
arrhythmia score) (P=0.32; Figure 27A) nor the incidence of VF (Figure 27B) and there 
were also no difference in the likelihood of an isolated heart to experience VF with the 
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phase of estrous. The severity of these arrhythmias was not correlated with the levels of 
estradiol or progesterone (Figure 27Cand D respectively). 
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Figure 27: No differences were seen between groups in the severity or incidence of ventricular 
arrhythmias in isolated rat hearts. Arrhythmia scores (A) and incidence of VF (B) were used to assess the 
severity of arrhythmias. There was also no correlation between the arrhythmia score and serum levels of 
estradiol (C) or progesterone (D) in isolated rat hearts. 
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Discussion 
It has been widely demonstrated in animal models that females exhibit a 
cardioprotective phenotype during their reproductive years (44, 64, 144, 152, 264). This 
has become a widely studied area with several different hypotheses as to how this 
occurs. However, there may be inherent variability in the data collected in these studies 
that arise from animals being in different phases of the estrous cycle. The goal of this 
study was to investigate if the estrous cycle has any effect on cardiovascular health and 
function in rat hearts during ischemia/reperfusion. Herein, we describe for the first time 
that the phase of the estrous cycle does not have any effect on the size of myocardial 
infarction or ventricular arrhythmias in rat hearts. Furthermore, we describe that there is 
no correlation between serum levels of 17-β estradiol or progesterone and infarction or 
arrhythmias. This study is important in establishing that the phase of estrous does not 
alter the results obtained in the isolated heart from female animals in studies where 
estrous cycle has not or cannot be standardized. 
 Several studies have investigated the role of exogenous estradiol on 
ischemia/reperfusion injury with several distinct mechanism put forth as possible 
explanations (for review see (32, 71)). In our study we saw no differences in the extent 
of injury with estrous phase or the amount of circulating estradiol. Although speculative, 
this may be because the effects of estrogen last longer than the duration of the estrous 
cycle in rats. Perhaps in larger animals, where cycle length is longer, differences may 
be observed.  
Several studies have shown that estradiol both augments activity of the PI3K/Akt 
pathway. Inhibition of PI3K and PKC has been shown to diminish cardiac function and 
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increase infarct size in female rats, but not in males (16). Using isolated hearts, Wang et 
al. found that female mice lacking estrogen receptor β (ERβ) exhibit diminished 
protection from myocardial infarction, inferring that increased activation of PI3K/Akt and 
decreased apoptosis may be responsible for the cardioprotective phenotype (264). 
Further demonstrating the possible anti apoptotic effects of estrogen, activation of a G-
protein coupled receptor that binds directly to estrogen has been shown to decrease 
mitochondrial permeability transition(33). 
 It has also been shown that acute pharmacological doses of exogenous 
estradiol lead to cardioprotection in the isolated heart and that lower, more physiological 
levels of estradiol have no acute effect (240).  The fact that we saw no difference in 
infarct size or correlation between infarct size and estradiol levels substantiates this 
observation. Debates within the literature as to the protective effects of exogenous 
estradiol administration may be due to the supraphysiological vs. physiological doses 
administered. The benefits to human health may also be limited as studies on hormone 
replacement therapy and morbidity have yielded conflicting results (for review see 
(190)). 
 Although studied less than estrogens and estradiol, progesterone is a major sex 
hormone that may affect cardiovascular function. Despite the fact that following the 
follicular phase, as progesterone levels increase, the risk of angina also increases (135) 
and is maintained after progesterone levels have dropped. High levels of progesterone 
have also been shown to be correlated with increased reactive oxygen species 
production in skeletal muscle (132). However, the fact that high progesterone levels 
may be associated with the development chronic heart failure, but not associated with 
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myocardial infarction (193) argues against a role for progesterone in 
ischemia/reperfusion injury. The inability to distinguish between the effects of estradiol 
and progesterone hinders investigators from concluding if their results are due to the 
protective effects of estrogen or the negative effect of progesterone.  
Conclusions 
 Despite the fact that several studies have shown that levels of estradiol and 
progesterone can have profound effects on cellular function, no one to date has 
investigated if circulating hormones affect ischemia/reperfusion injury. This study 
presents several novel findings, 1) circulating hormone levels during the estrous cycle 
do not influence cardiac ischemia/reperfusion injury and 2) serum levels of estradiol and 
progesterone are not correlated with infarct size or arrhythmia. These findings were 
confirmed in both the in-vivo and ex-vivo model, demonstrating that the effects of 
circulating hormones do not influence ischemia/reperfusion injury in rat hearts. This 
study is important in establishing the validity of data obtained from female rats in studies 
where estrous cycle was not determined. 
 
  
Appendix C: Figure reproduction 
   
 
Figure 28: Percentage breakdown of deaths due to CVD (United States: 2006, 
preliminary). Taken from (162). 
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Figure 29: Mechanisms by which myocardial ischemia can lead to cell death and 
myocardial infarction. Taken from (200). 
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Figure 30: Putative sequence of events leading to exercise-induced cardioprotection. 
Postulated ‘triggers’ of exercise-induced cardioprotection are denoted in green, with 
end-effectors labeled in red font.  Images of nucleus and myofilaments obtained from 
(24, 266) respectively. 
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A. 
 
B. 
 
Figure 31: Pathophysiological changes in rodent cardiac tissue during ischemia (A) 
and reperfusion (B). Postulated mechanisms involved in exercise-preconditioning 
noted in red font.  Heart image modified from (170).  Abbreviations: ∆Ψ p, sarcolemmal 
membrane potential, ∆Ψ m, mitochondrial membrane potential; sarcKATP, sarcolemmal 
ATP-sensitive potassium channels. 
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Figure 32: Exercise delays the onset of ventricular arrhythmias during sustained thiol 
oxidation. A. Representative left ventricular developed pressure (LVDP; black trace) and 
volume-conducted electrocardiogram (ECG; gray trace) recordings from a sedentary 
animal approximately 39 minutes into diamide treatment. The transition to ventricular 
arrhythmia and subsequent loss of pump function is noted with an arrow. B: 
Representative trace from an exercised animal during the same duration of diamide 
treatment as the sedentary trace. C Mean time to onset of ventricular arrhythmia 
following sustained diamide treatment; *, P<0.05 vs. Sed. N = 8 per group. Mean ± 
S.E.M.  
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Figure 33: Ex decreases the severity of arrhythmias in the isolated rat heart exposed 
to reversible treatment with the thiol oxidant diamide (30 min), followed by a 30 minute 
washout period.  A: Arrhythmia scores (calculated from System A) between Sed and 
Ex animals during/after the diamide treatment. B: Arrhythmia scores (calculated from 
System B) between Sed and Ex animals during/after the diamide treatment.  C: 
Percentage of hearts in each group that experienced an episode of VF. D: Summary 
of hearts in each group that experienced a fatal (non-spontaneously reverting) 
ventricular arrhythmia; *, P<0.05 vs. Sed during diamide treatment; +, P<0.05 vs. Ex 
during diamide;  #, P<0.05 vs. Sed during washout.  N= 7 per group. Mean ± S.E.M.  
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Figure 34: Incidence of reperfusion arrhythmias in hearts exposed to 30 
minutes of global ischemia and 30 minutes of reperfusion. A: Arrhythmia 
scores (calculated from System A) for hearts 15 minutes into reperfusion. B: 
Arrhythmia scores (calculated from System B) for hearts 15 minutes into 
reperfusion. C. Summary of hearts in each group that experienced an episode 
of VF. D. Incidence of non-reverting (fatal) arrhythmia during reperfusion for 
hearts in the study.  *, P<0.05 vs. Sed. N = 7 per group. Mean ± S.E.M. 
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Figure 35: Left ventricular developed pressure (LVDP) during diamide treatment and 
washout for Sed (black circles) and Ex (gray circles) groups. Hearts were perfused with 
200 µM diamide for 30 minutes, followed by a 20 minute washout; *, P<0.05 Main 
effect; **, P<0.05 Bonferonni post hoc for time. N= 7 per group. Mean ± S.E.M. 
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Figure 36:  Ex delays the increase in ROS fluorescence and decreases cell death in 
isolated ventricular myocytes exposed to oxidative stress.  A: Representative images 
over time for Sed and Ex myocytes. Black and white pictures represent bright field 
images of myocytes at the beginning and end of each experiment, and fluorescence 
traces in between are fluorescence images from cells loaded with the ROS sensor CM-
DCF.  B: Representative CM-DCF traces from Sed (black line) and Ex (gray line) 
myocytes. C: Average time to inflection for both groups. D: Survival curve for Sed 
(black) and Ex (gray); *, P<0.05 for Sed versus Ex myocyte survival. N = 18 (from 4 
animals) for Sed and 25 (from 4 animals) for Ex. Mean ± S.E.M.  
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Figure 37: Myocardial content of total glutathione (GSHt), oxidized glutathione (GSSG), 
and ratio of reduced to oxidized glutathione (GSH/GSSG). All tissue collected 
immediately after the completion of each perfusion protocol. A: total glutathione (GSHt) 
content. B: oxidized glutathione (GSSG) content. C: ratio of reduced to oxidized 
glutathione (GSH/GSSG) in hearts. *, P<0.05 vs. Sed at Baseline; #, P<0.05 vs. Ex 
Baseline; +, P<0.05 vs. Ex until arrhythmia; Mean ± S.E.M.   
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Figure 38: Glutathione reductase (GR) activity in hearts exposed to sustained thiol 
oxidation. Hearts were cut down after the onset of ventricular arrhythmia (time-points 
noted in Figure 1) and analyzed for GR activity.  A subset of exercised hearts was cut 
down at the mean arrhythmia onset time for sedentary hearts (39 minutes).   *, P<0.05 
vs. Sed; #, P<0.05 vs. Ex.  N = 8 per group. Mean ± S.E.M. 
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Figure 39: Basal changes in cardiac glutathione reductase (GR) and glutathione 
peroxidase (GPx) enzyme activity for sedentary (Sed) and exercise trained (Ex) 
hearts.  *, P<0.05.  N = 6 for Sed and 5 for Ex. Mean ± S.E.M. 
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Figure 40: Exercise-induced preconditioning abolished with apocynin treatment. * 
P<0.05 vs. Sed, # P<0.05 vs. Ex, + P<0.05 vs. Sed  and  MTP, @ P<0.05 vs. Ex and 
MTP. Mean ± S.E.M. 
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Figure 41: Inhibiting NAD(P)H oxidase generated ROS prior to exercise blunts 
increases in glutathione reductase activity. * P<0.05 vs. Sed, # P<0.05 vs. Ex 
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Figure 42: Redox modification of GR activity in Sed and Ex left ventricular 
homogenates. * P<0.05 vs. Sed. 
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Figure 43: No differences in GR protein expression between groups. 
 
 
 SedSed ExEx Ex/ApoEx/Apo 
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Figure 44: GR inhibition abolishes exercise-induced preconditioning from myocardial 
infarction and ventricular arrhythmias. Infarct size (A)  and arrhythmia (B) data from 
isolated hearts perfused with BCNU *, P<0.05 vs. Sed; #, P<0.05 vs. ; Data presented 
as mean ± s.e.m.    
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Figure 45: Infarct size in isolated guinea pig hearts exposed to 20 minutes of ischemia 
and 2 hours of reperfusion. Whole time = compound administered both before and after 
ischemia; @ reperfusion = compound administered only during reperfusion; P < 0.05 
versus control (ANOVA). 
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Figure 46: Bendavia significantly abolished ROS-dependent cell death, but the extent 
of cell death during hypoxia as well as ROS-independent cell death during 
reperfusion was similar to control.  Survival plot for myocytes in the study exposed to 
hypoxia and reoxygenation. Each cell death event is noted as a downward step in the 
survival curve. *, P<0.05 versus control for the reoxygenation period. 
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Figure 47: Cellular ROS production during hypoxia/reoxygenation. A: Representative 
fluorescence images of cardiac ventricular myocytes loaded with the ROS sensor CM-
DCF.  ROS bursts during reoxygenation preceded cell death, and Bendavia treatment 
prevented ROS-induced cell death. B: Representative fluorescence intensity traces for 
cells in the study.  CM-DCF fluorescence is normalized to the basal fluorescence (Fo) 
for each cell at the end of hypoxia.   
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Figure 48: Contribution of ROS bursts to myocyte death during 
hypoxia/reoxygenation. 
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Figure 49: Mitochondrial membrane potential (∆Ψm) in myocytes during cellular 
hypoxia/reoxygenation. A. Representative fluorescence images of myocytes loaded with 
the ∆Ψm sensor TMRM.  ∆Ψm collapse often preceded cell death, and treatment with 
Bendavia improved the capacity to maintain ∆Ψm.  B. Representative fluorescence 
intensity traces for cells in the study.     
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Figure 50: Representative images from vaginal cytology for Proestrus (A), Estrus (B), 
Metestrus (C), and Diestrus (D) phases of the estrous cycle. (E) Daily changes in the 
phase of estrous in our animals.   
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Figure 51: No difference in infarct size between the phases of the estrous cycle. Data from 
the ex vivo (A) and in vivo (B) hearts. There was also no correlation between infarct size and 
serum levels of estradiol (C) or progesterone (D) in isolated rat hearts. 
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Figure 52: No differences were seen between groups in the severity or incidence of 
ventricular arrhythmias in isolated rat hearts. Arrhythmia scores (A) and incidence of VF 
(B) were used to assess the severity of arrhythmias. There was also no correlation 
between the arrhythmia score and serum levels of estradiol (C) or progesterone (D) in 
isolated rat hearts.  
